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1. Abstract 
 
 
 
Dipyridamole belongs to the category of antiplatelet drugs 
commonly used in cardiovascular disease, here we want test its effectiveness in 
the treatment of triple-negative breast-cancer. In-vitro assays were used to 
analyze the perturbations induced by dipyridamole on the cell cycle, on cell 
growth and motility. We also want to assess the dipyridamole action on Wnt, 
NF-kB and ERK1/2-MAPK signaling pathways that are overactive in such 
tumors. Here we provide the evidence that dipyridamole is able to perturb also 
in vivo the activation of these important pathways and inhibit the infiltration of 
immune cells within the tumor mass that may control the tumor growth and 
propagation of metastasis. Xenograft mice bearing triple-negative breast-cancer 
4T1-Luc cells were generated to investigate the primary tumor growth, 
metastasis formation and serum inflammatory cytokines levels. In vivo, 
dipyridamole significantly reduced primary tumor growth and metastasis 
formation, indeed treatment with 60 mg/kg/day dipyridamole reduced mean 
primary tumor size by 76.7% (p = 0.0429), while treatment with 30 mg/kg/day 
dipyridamole resulted in an almost a total reduction in metastasis formation (p 
= 0.0292). Immunohistochemical analyses reveal significant effects of 
dipyridamole on the Wnt, ERK1/2-MAPK and NF-kB pathways in primary 
tumor animal models. In vivo dipyridamole decreased activated β-catenin by 
38.64 % (p <0.0001), phospho-ERK1/2 by 25.05 % (p =0.0129), phospho-p65 
by 67.82 % (p <0.0001) and doubled the expression of IkBa (p = 0.0019), thus 
revealing significant effects on Wnt, ERK1/2-MAPK and NF-kB pathways in 
4T1-Luc xenograft animal model. Moreover dipyridamole significantly 
decreased the infiltration of tumor-associated macrophages and myeloid-
derived suppressor cells in primary tumors (p <0.005), and the inflammatory 
cytokines levels in the sera of the treated mice. We suggest that when used at 
appropriate doses and with the correct mode of administration, dipyridamole is 
a promising agent for breast-cancer treatment, thus also implying its potential 
use in other cancers that show highly activated Wnt, ERK1/2-MAPK and NF-
kB pathways. 
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2. Background 
 
 
 
2.1 Breast cancer 
 
Breast cancer is the most common cancer among American 
women and is a leading cause of cancer death worldwide. One in every eight 
women in the United States develops breast cancer. According to the American 
Cancer society, over 200,000 new cases of invasive breast cancer are 
diagnosed each year. Nearly 39,510 women in United States died of breast 
cancer in 2012. There are over 2.5 million breast cancer survivors in the United 
States (Brewster A et al. 2001). 
It is a complex and heterogeneous disease, including tumor size and 
histological features associated with distinct biological characteristics that 
naturally appear to have highly heterogeneous clinical developments (Brewster 
A et al. 2001, Jemal A et al. 2011). Moreover, data obtained from gene 
expression studies suggest the presence of different molecular subtypes of 
breast cancer that may respond to different types of therapy (Brewster A et al. 
2001, Jemal A et al. 2011).  
The lesions that occur in mammary gland can give rise to: 
 Typical hyperplasia that occurs when additional layers of normal 
appearing cells are found. The diagnosis of this lesion is associated to a low 
risk for developing invasive cancer;  
 Atypical ductal hyperplasia involves extra abnormal appearing cells 
which do not meet the full criteria for a cancer diagnosis, but confer an 
approximate fourfold risk for the development of invasive cancer;  
 Ductal carcinoma in situ (DCIS) that consists of cancer cells growing 
within the basement membrane;  
 Infiltrating ductal or invasive carcinoma that occurs when cancer cells 
invade the basement membrane. In this case, invasive breast cancer is 
categorized by whether evidence of metastasis to the regional lymph nodes is 
apparent, either by a lymph node dissection or by a sentinel node examination 
(Perou CM. 2011).  
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Figure 1. Breast cancer morphology and cancer progression A) Breast cancer 
morphology in cross section and description of different type of breast cancer: lobular 
cancer that arises from lobular cells, ductal cancer from cells of milk ducts; these two 
types of cancer remain within the basement membrane and haven’t infiltrating 
characteristics while in infiltrating breast cancer the malignant cells are able to invade 
the surrounding tissue and metastatize. B) Progression of breast cancer: the normal 
duct/lobule consists in inner layer of luminal epithelial cells, surrounded by 
myoepithelial cells and a basement membrane. Ductal cancer in situ (DCIS) consists 
of cancer cells growing within the basement membrane; infiltrating ductal or invasive 
carcinoma is made when cancer cells invade the basement membrane. 
 
 
Over the past few years, knowledge of the molecular 
mechanisms underlying tumorigenesis has allowed the identification of an 
increasing number of biomarkers, which have been correlated with cancer 
prognosis or used as predictors of response to specific treatments, with varying 
degrees of success (Domchek, S.M. and Weber, B.L 2002). The clinical and 
pathological prognostic factors currently used in cases of primary breast cancer 
include the tumor stage, the tumor size, the tumor grade, nodal status, age and 
vascular invasion. The biological factors used are estrogen and progesterone 
receptor (ER and PR, respectively) status, proliferative index (Kuru, B.et al. 
2003, Morabito, A. et al. 2003), retinoic acid receptor [RAR]-β), members of 
the HER/erbB family, and selected tumor suppressor/susceptibility genes (e.g., 
p53, BRCA1, and BRCA2). Prognostic factors are used to aid clinical decision 
making and help to select the appropriate treatment for individual patients and, 
furthermore, to allow comparison between groups of patients at similar risks of 
recurrence or death. 
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Since 1990, the mortality from breast cancer has decreased 
primarily as a result of increases in early detection and improved treatment 
options. These improved treatment options are not uniformly efficacious 
against all breast cancers because breast cancer is not a single malignant cell 
type. Instead, breast cancers are heterogeneous consisting of a conglomeration 
of immunohistologically different malignant cells. The particular genes that a 
cancer cell will express determine the receptors and biomarkers that will be 
present on its cell membrane. This gene expression profile can be identified 
and allows classification of the cancer into subtypes. Four subtypes are 
recognized based on their gene expression profiles: luminal A, luminal B, 
human epidermal growth factor receptor (HER-2) positive, and basal like. In 
addition to aiding classification of the breast cancers into subtypes, biomarkers 
have become the targets for development of unique chemotherapies. Specific 
anti-hormonal therapies are now available against the hormonal receptors for 
estrogen (ER) and progesterone (PR) as well as human HER-2/neu. 
Fortunately, these anti-hormonal and molecular therapies are highly efficacious 
and have greatly reduced the mortality in women with breast cancers whose 
gene expression patterns produce susceptible targets to this line of therapy.  
 
 
 
2.2 Triple-negative breast-cancer: one step ahead 
 
Triple-negative breast-cancer (TNBC) accounts for 
approximately 15% of breast cancers. Although recently in the limelight and 
frequently discussed, TNBC is not a new type of breast cancer. Indeed, the 
term has recently been coined to describe a subtype of breast cancer that lacks 
expression of the estrogen receptor (ER) and progesterone receptor (PR) and 
does not overexpress human epidermal growth factor 2 receptor (HER2) 
protein. TNBC is an important area of research for both researchers and 
clinicians alike because TNBC is a poor prognostic factor for disease-free and 
overall survival, no effective specific targeted therapy is readily available for 
TNBC. Approximately 80% of TNBC are classified as basal like. As neither of 
the hormone receptors nor the HER-2 is expressed in TNBC, the hormonal and 
molecular therapies used in other subtypes are not effective. Therefore, at this 
time, therapy options for TNBC are restricted to conventional systemic 
cytotoxic chemotherapies. Further, TNBC patients need highly effective 
therapy because these cancers are characterized by greater aggressive behavior, 
including earlier relapses, distinct patterns of metastases, and higher rates of 
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mortality than other breast cancers. Overall, TNBC has a poorer prognosis and 
higher rate of early relapse than other types of invasive breast cancer (Foulkes 
WD et al. 2010, Carey L et al. 2010). One clear approach to limiting the 
devastation of cancer is to identify it before metastasis occurs. The other 
approach is to understand the metastatic process and develop effective 
strategies to halt it. 
 
 
 
2.3 Cancer metastasis and platelets: a causal relationship  
 
In breast cancer, metastatic spread is responsible for almost all 
cancer deaths. Due to the heterogeneity and individual variability of the disease 
are not currently present guidelines for the treatment of such tumors. Recent 
therapeutic developments have led to a steady increase of treatment efficacy 
and an improvement in the prognosis of metastatic disease. However, despite 
significant advances in diagnosis and treatment of breast cancer, metastatic 
disease remains incurable, and treatment goals are focusing on prolonging 
survival and provide only a palliative control of symptoms. Breast cancer has 
the potential to spread to almost any region of the body, with the bone, lung 
and liver representing the most common secondary locations. However, as 
treatment options for advanced metastatic breast cancer are limited, this stage 
of the disease is responsible for the highest number of breast cancer deaths. 
Metastasis is a complex process composed of numerous distinct steps involving 
progressive alterations in the tumor cell, as well as tumor-induced alterations of 
the secondary microenvironment (Welch D.R. et al. 2000, Steeg PS 2000). The 
formation of metastases requires highly complex molecular and cellular 
processes, during which tumor cells must detach from their tissue of origin 
(primary tumor), invade surrounding tissues, penetrate blood and/or lymphatic 
vessels, reach distal sites, and be able to colonize the secondary organs.  
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Figure 2. The tumor metastatic process. At the primary tumor site, tumor cells 
invade into the lymphatic vessels or directly into the circulation. Once in the 
bloodstream, tumor cells must survive and avoid immune attack to extravasate. Arrest 
is most often due to the size restriction in capillary beds but can involve specific 
adhesive interactions. The process by which tumor cells form micro-metastases and 
then progressively grow and vascularize (macro-metastases) in a distant organ is 
termed metastatic colonization. Metastatic colonization involves reciprocal 
interactions between tumor cells and cells in the microenvironment of the distant 
organ, and can pause for periods of dormancy. 
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At the base of the metastatic process there is an active 
involvement of the haemostatic system and tumor microenvironment; tumor 
cells in the circulation have the ability to interact with blood components, such 
as platelets, giving rise to the formation of microemboli. These aggregates 
allow the tumor cell to survive to mechanical and immunological attacks which 
may encounter in the blood vessels and reach the organs and tissues where they 
form new tumor foci. The physiologic conditions of the blood provide a hostile 
environment for tumor cells. The rapid destructions of tumor cells have been 
attributed to a variety of mechanisms, including natural killer cells, 
macrophages, polymorphonuclear leukocytes, antibodies, and mechanical 
trauma. These mechanisms could operate while tumor cells were in circulation 
in large blood vessels or after they had lodged in capillaries. Homotypic 
aggregation of tumor cells can influence their implantation in capillaries and 
has a permissive effect on the frequency of metastases. Heterotypic interactions 
of tumor cells with platelets, lymphocytes or polymorphonuclear leukocytes 
have been observed to facilitate the formation of metastases (Tsuruo T et al. 
2008). 
 
 
Figure 3. Schematic representation of platelets aggregation during hematogenous 
metastasis formation. After migrating through the host’s blood stream, tumor cells 
induce platelets aggregation and the platelet-coated tumor cells are then protected 
from immunological assault in the circulation. Another survival advantage is the 
tendency for the large tumor-platelet aggregate to embolize the microvasculature at a 
new extravasation site. Then, tumor cells extravasate and proliferate within the foreign 
tissue (metastatic site). 
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2.4 Role of microenvironment in primary tumour growth and 
metastatic process 
 
The ability of tumor cells to grow in the primary site of tumor, 
disseminate, survive and proliferate at the new site is also dependent on 
favorable interactions between the tumor cell and the ectopic 
microenvironment (Chambers, A.F et al. 2002, Spano D. and Zollo M. 2012). 
Understanding the basic biology of each step of these interaction processes is 
essential for the development of improved therapeutic strategies for breast 
cancer.  
In the 1980s, Stephen Paget proposed the ‘seed and soil’ theory 
for metastasis whereby the ‘seed’ (tumor cells) is postulated to only grow when 
it finds a suitable ‘soil’ (environment) (Paget S et al. 1989). This theory is 
being revisited, as increasing evidence points to the tumor microenvironment 
as a critical factor in metastasis. The microenvironment of metastatic tumor 
cells is critical for tumor cell proliferation. A suitable microenvironment is a 
requirement for and equally important in establishing tumor growth and 
malignant progression (Psaila B et al. 2006). Many different specialized cells, 
including fibroblasts, immune cells, endothelial cells and mural cells of the 
blood and lymphatic vessels, together with the extracellular matrix (ECM) 
make up the microenvironment which influences tumor progression (Kalluri R 
et al. 2006, Folkman J et al. 2004, De Palma M et al. 2003). Malignant cells 
constantly interact with cells of the microenvironment at both primary and 
metastatic sites (Geiger TR et al. 2009, Joyce JA et al. 2009, Kuhn NZ et al. 
2010, Psaila B and Lyden D 2009). These interactions pave the way for the 
progression of ‘in situ’ breast cancer to metastatic breast cancer (Coghlin C et 
al. 2010). An important role in the tumor development and malignant 
progression is played by the tumor infiltrating-immune inflammatory cells. 
Once recruited into the tumor microenvironment, these cells can contribute to 
the malignant progression of the cancer-cell phenotype. Moreover they 
establish a complex network of interplay that contributes to the promotion and 
maintenance of an immunosuppressive microenvironment, which itself 
promotes immune escape, and as a consequence, enhances tumor progression. 
Infiltrating immune cells are normal constituents of tumors. 
They operate in conflicting ways, by either antagonizing or promoting tumors. 
Indeed, it has been hypothesized that the balance between the tumor 
antagonizing inflammatory cells and the tumor promoting inflammatory cells 
modulates tumor progression. The tumor-promoting inflammatory cells include 
macrophage subtypes, mast cells and neutrophils, as well as T and B 
lymphocytes (Poste G, and Fidler IJ 1980). These cells can secrete several 
signaling molecules that serve as effectors of their tumor promoting actions. 
These include several chemokines and cytokines that amplify the inflammatory 
state. In addition, these infiltrating immune cells can produce proangiogenic 
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and/or proinvasive matrix-degrading enzymes, including MMP9 and other 
MMPs, cysteine cathepsin proteases, and heparanase (Hunter KW et al. 2008). 
As a consequence of the expression of those effectors, these cells induce and 
support tumor angiogenesis, which stimulates cancer-cell proliferation, 
facilitates tissue invasion, and sustains metastatic dissemination (Talmadge JE 
and Fidler IJ 2010). Within the tumor mass, in addition to fully differentiated 
immune cells, a variety of partially differentiated myeloid progenitors have 
been identified. These cells are intermediates between the circulating cells of 
bone marrow origin and the fully differentiated immune cells in normal and 
inflamed tissues, and they show tumor-promoting activities. Of particular 
interest for their multiple functions are the Myeloid-Derived Suppressor Cells 
(MDSCs). 
MDSCs comprise a phenotypically heterogeneous population of 
immature myeloid cells at different stages of differentiation. They derive from 
bone-marrow progenitors that have not completed their maturation into 
granulocytes, monocytes or dendritic cells (Gabrilovich DI and Nagaraj S. 
2009) Normally, MDSCs are in the bone marrow of healthy individuals, 
although they preferentially accumulate in the spleen and blood of tumor 
bearers (Nagaraj S and Gabrilovich DI 2008). In mice, these cells express the 
membrane antigens Gr1 and CD11b, and based on the expression of different 
epitopes of Gr1, they can be further subdivided into the granulocytic, as 
CD11b+ Gr1+ (Ly6G+), and monocytic, as CD11b+ Gr1+ (Ly6C+ Ly6G)) 
subclasses (Nagaraj S and Gabrilovich DI 2010). In human, MDSCs appear to 
be more like a “family of MDSCs”, which includes different cell populations 
with varying phenotypes and biological diversities. The role of these cells in 
human cancer progression is underlined by the correlation between the 
expansion of the MDSCs pool, the tumor stage and the evidence of metastasis 
formation (Diaz-Montero CM et al. 2009). The major function of MDSCs is to 
orchestrate other cells of the immune response, to promote an 
immunosuppressive and anti-inflammatory phenotype, which results in tumor 
immune escape (Yang L and Moses HL 2008). Indeed these cells can block the 
activity of T-lymphocytes and NK cells and can induce the M2 polarization of 
tumor-associated macrophages (TAMs) through secretion of high levels of IL-
10. For this function in tumor-bearing hosts, MDSCs need to expand in the 
lymphoid organs and to subsequently be recruited to the primary tumor site 
(Ostrand-Rosenberg S and Sinha P 2009), processes being directed by tumor-
associated inflammation, and by angiogenic and chemoattractant factors.  
The other important component of the tumor microenvironment 
is the Tumor-Associated Macrophages (TAMs) (Solinas G et al. 2009). 
Macrophages constitute an extremely heterogeneous population. They originate 
from blood monocytes that are not fully differentiated cells, and they are 
profoundly susceptible to several environmental stimuli. When recruited into 
peripheral tissues from the circulation, monocytes can differentiate rapidly into 
distinct, mature macrophages, which have specific immunological functions. 
TAMs originate from blood monocytes that are recruited at a tumor site by 
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molecules that are produced by neoplastic and stromal cells. In the tumor 
milieu, TAMs carry on their pro-neoplastic role by influencing fundamental 
aspects of tumor biology: they can produce molecules that affect neoplastic cell 
growth directly (e.g., EGF), enhance neoangiogenesis, tune inflammatory 
responses and adaptive immunity, and catalyze structural and substantial 
changes in the ECM compartment (Mantovani A et al. 2008, Pollard JW 2008). 
Several chemokines are players in this process as well as cytokines and the 
growth factor M-CSF (De Nardo DG 2008, Balkwill F 2004, Allavena P et al. 
2008). In particular, CCL2 is the main molecule that is involved in monocyte 
recruitment. Its expression correlates with TAMs abundance in many human 
tumors, including those of ovarian, breast and pancreatic cancers (Balkwill F 
2004). Furthermore, TAMs can themselves produce CCL2, which suggests that 
they can act as an amplification loop. Within the tumor mass, the monocytes 
are surrounded by several signals that can induce their differentiation towards 
mature M2-polarized macrophages. These macrophages have a pivotal role in 
tumor growth and progression. The role of TAMs in angiogenesis is 
emphasized by the correlation between their high numbers and the high 
vascular grades in many tumors, including gliomas, squamous cell carcinomas 
of the esophagus,breast, bladder and prostate carcinomas (Koide N 2004). 
They release the growth factors VEGF, PDGF, TGF-β, and members of the 
FGF family (Bingle L et al. 2006). TAMs secrete the angiogenic factor 
thymidine phosphorylase, which promotes endothelial cell migration in vitro 
(Hotchkiss KA, et al.2003), and they also produce several angiogenesis-
modulating enzymes and chemokines that are involved in angiogenic 
processes. Within the primary tumor microenvironment, at least two 
mechanisms have been proposed by which TAMs facilitate tumor metastasis. 
The first relates to the secretion of proteases within the tumor 
microenvironment that can digest the tumor basement membrane, thus 
facilitating tumor-cell escape. A second mechanism is direct through 
enhancement of an early stage of the metastatic cascade (Fidler IJ 2003). 
Macrophage-produced EGF increases the motility and invasiveness of 
malignant cells. Finally, within the tumor microenvironment, TAMs have 
strong immunosuppressive activity, not only through their production of IL-10, 
but also by their secretion of chemokines (e.g., CCL17 and CCL22), which 
preferentially attract T-cell subsets that are devoid of cytotoxic functions, such 
as regulatory T (Treg) cells and Th2 lymphocytes.   
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Figure 4. The tumor microenvironment. The communication between the tumor 
cells and the surrounding cells -the microenvironment- helps drive the process of 
tumor progression. So going from normal to benign, benign to malignant, malignant to 
metastatic is driven not only by what's happening inside the tumor cell itself but also 
by what's happening around it. Overview of the network of connections within the 
tumor microenvironment, indicating the cells that populate the tumor 
microenvironment and the complex interplay between these cells. (A) The tumor cells 
secrete several cytokines that modulate the recruitment and function of the stromal 
cells. In particular, the RANTES cytokine (B) stimulates CAFs to externalize the 
S100A4 protein, while SCF (C) promotes the recruitment and activation of mast cells. 
The S100A4 secreted by CAFs (D) has several effects on the tumor cells: stimulation 
of tumor-cell survival and migration; up-regulation of MMPs; down-regulation of 
TIMPs; activation of the NF-kB and MAP kinase pathways; and finally, up-regulation 
of RANTES. This thus generates a signal amplification loop. Moreover, S100A4 
induces the infiltration of T cells (E). CAFs provide oncogenic signals to tumor cells 
(F), including TGF-β and HGF, and secrete CCL2/MCP1 and SDF1 (G), which are 
involved in the recruitment of MDSCs and TAMs. Within the tumor 
microenvironment, the mast cells induce proliferation, migration and invasion of 
cancer cells, promote degradation of the ECM, induce angiogenesis, and recruit and 
modulate MDSCs function (H). T cells secrete G-CSF (I), thus further recruiting 
MDSCs. TAMs produce EGF and signaling molecules of the Wnt pathway (J), which 
induce tumor-cell growth and invasion. Within the tumor microenvironment, the 
MDSCs have several functions. They promote angiogenesis, invasion and metastasis, 
favor recruitment and expansion of Treg cells, inhibit T-cell expansion and activation, 
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and inhibit natural killer cells and B cells (K). The dashed ellipses indicate the flow of 
consecutive actions (Spano D and Zollo M 2012). 
 
 
 
 
2.5 Dipyridamole in cancer therapy 
 
Dipyridamole belongs to the category of antiplatelet drugs 
commonly used in cardiovascular disease that has several antithrombotic 
effects, including reduced platelet activation through adenosine 3’,5’-cyclic 
monophosphate and guanosine 3’,5’-cyclic monophosphate phosphodiesterase 
inhibition, antiatherogenesis through antioxidant properties, and inhibition of 
restenosis by suppression of smooth muscle proliferation (Eisert WG 2002). 
Furthermore, it is an effective inhibitor of the human breast-cancer-resistance 
protein BCRP/ABCG2 which is a drug efflux transporter, and which confers 
resistance to a large number of chemotherapeutic agents by enhancing the drug 
efflux. Based on the observation that there is a causal relationship between 
platelets and metastasis formation it is not surprising that anti-coagulants and 
agents that interfere with platelet aggregation, such as anti-thrombins, can 
prevent tumor metastases. The clinic potential of dipyridamole for the 
treatment of metastasis in human cancers, such as colorectal cancer, non-small-
cell lung cancer, renal cell carcinoma, melanoma, pancreatic adenocarcinoma 
and stomach cancer, has been tested in combination with cytotoxic drugs 
(Hejna M et al. 1999, Isacoff WH et al. 2007, Raschko JW et al. 2000, Burch 
PA et al. 2000) Furthermore, recently, the clinic potential of dipyridamole in 
combination with cytotoxic alkylphospholipid perifosine for the treatment of 
metastasis in breast cancer xenograft animal models has been assessed (Wenzel 
J et al. 2009, Wenzel J et al. 2010). Dipyridamole has also been shown to 
enhance in vitro TRAIL tumoricidal activity (Goda AE et al. 2008).  
These studies, in which the dipyridamole was used in 
combination with cytotoxic drugs, make more difficult the evaluation of the 
clinic potential of dipyridamole for the primary tumor and metastasis 
treatments. To our knowledge the clinic potential of dipyridamole alone for the 
metastasis treatment has not been yet investigated. Similarly the clinic potential 
of dipyridamole alone for the primary tumor treatment has not been 
investigated before. 
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3. Aims of the study 
 
 The aim of this work is to investigate the potential role of 
dipyridamole as a single agent in the prevention of tumorgenesis and 
metastasis formation in multiple models of triple-negative (estrogen and 
progesterone receptor-negative, Her-2 normal) breast cancers, a subtype that 
has few effective therapies in which metastatic disease is the major cause of 
death. Here, the attention was focused on the molecular mechanisms by which 
dipyridamole exerts its tumor growth inhibition and on the more effective 
method of drug administration. These data will provide important scientific 
indications to assess the effectiveness of this drug, approved by Food and Drug 
Administration, for developing in future more targeted treatments for triple-
negative breast-cancer patients. 
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4. Materials and Methods 
 
 
4.1 Proliferation assay 
 
Proliferation assays were performed using the CellTiter 96 
Aqueous One Solution Cell Proliferation Assay (Promega). The 4T1-Luc cells 
(2 ×10
3
/well) and MDA-MB-231T cells (3 ×10
3
/well) were plated into 96-well 
plates and treated with PBS-PEG (control) or 10 μM, 50 μM or 100 μM 
dipyridamole, for 0, 24, 48 and 72 h. Each experimental point was assessed in 
quadruplicate. The medium supplemented with PBS-PEG or dipyridamole was 
replaced twice daily. For each experimental point, 20μl (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetra 
zolium) (MTS) solution (1.90 mg/ml) was added to each well, and the cells 
were incubated for 2 h at 37 °C. Absorbance was then measured at 490 nm 
using a microtitre plate reader (VICTOR3 1420 Multilabel Counter, Perkin 
Elmer). For each experimental point, the means of absorbance and their 
standard errors (SE) were calculated. A total of two independent sets of 
experiments were performed. 
 
 
 
4.2 Flow cytometry 
 
The 4T1-Luc and MDA-MB-231T cells were treated with PBS-
PEG (control) or dipyridamole (10, 50, 100 μM) for 24 h. The medium 
supplemented with PBS-PEG or dipyridamole was replaced twice daily. For 
the cell-cycle analysis, after treatment, the cells were resuspended in PBS 
containing 0.002% Nonidet P40, 12.5 μg/ml ribonuclease A, and 20 μg/ml 
propidium iodide, incubated at room temperature for 3 h in the dark, and 
analyzed on a FACScan flow cytometer (Becton Dickinson Immunocytometry 
Systems). For each experimental point, the cell-cycle analysis was performed 
in triplicate, and two independent sets of experiments were performed. For the 
evaluation of the percentages of CD49f+ cells, after treatment, 2 ×10
5
 4T1-Luc 
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cells were incubated for 30 min with a FITC-conjugated anti-CD49f antibody 
(BD Pharmingen) and analyzed using a BD FACS Aria flow cytometer (BD 
Biosciences, Oxford, UK). The collected data were analyzed using the FACS 
Diva software, version 6 (BD Biosciences). Each experimental point was 
assessed in duplicate, and two independent sets of experiments were 
performed. 
 
 
 
4.3 Cell migration assays 
 
The effects of dipyridamole on cell migration were analyzed by 
using chamber inserts (24-well format, polycarbonate membrane filter, 8 μm 
pore size; Corning). Here, 2.5 ×10
4
 4T1-Luc cells or 1×10
5
 MDA-MB-231T 
cells were seeded into the upper chamber in DMEM without fetal bovine 
serum, in the presence of PBS-PEG (control) or dipyridamole (10, 50, 100 
μM). The DMEM in the lower chamber contained fetal bovine serum (5% for 
4T1-Luc cells, 10% for MDA-MB-231T cells), which served as the 
chemoattractant; this was also supplemented with PBS-PEG or dipyridamole 
(10, 50, 100 μM). After 4 h incubation at 37 °C, the cells migrating to the 
lower membrane surface were fixed and stained with hematoxylin/eosin. The 
4T1-Luc cells were counted per membrane under a light microscope. The 
MDA-MB-231T cells were photographed and counted in three random fields 
per membrane at 10× magnification under a light microscope. Each 
experimental point was in duplicate, and two independent sets of experiments 
were carried out. For each experimental point, the mean ±SE of the number of 
migrated cells per membrane/field were calculated. 
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4.4 xCelligence system 
 
The Real-Time Cell Analysis (RTCA) Instrument developed by 
Roche uses an xCelligence system that is based on the Real-Time Cell 
Electronic Sensor (RT-CES) system, which allows label-free dynamic 
monitoring of cell proliferation and viability in real-time. The electronic 
readout of impedence is expressed as arbitrary units and called the cell index 
(CI). The cell culture conditions on the sensor device were the same as those 
described above. Proliferation assays in real time were performed as previously 
described (Yang L and Moses HL 2008). Here, 8 ×10
3
 4T1-Luc cells/well or 2 
×10
4
 MDA-MB-231T cells/well were plated into each sensor well of an E-plate 
16 (ACEA Biosciences, Inc). Four replicates for each experimental point were 
used. After the DMSO (control) or dipyridamole addition, the CI was 
automatically and continuously monitored every 5 min for up to 54 h. A total 
of two independent sets of experiments were performed. 
 
 
 
4.5 Luciferase reporter assay 
 
The HEK293T cells were seeded into 96-well plates at a density 
of 1.35 ×10
4
 cells/well and grown for 24 h. The cells were then transfected 
using CaCl2 and 2× HBS reagent (50 mM HEPES, 280 mM NaCl, 1.5 mM 
Na2HPO4, pH 7) with 15 ng Tk-Renilla luciferase plasmid, 65 ng β-catenin-
cmyc-pCAN plasmid, or its empty vector as control, and 25 ng of a firefly 
luciferase reporter construct, as either: TOP-FLASH, containing four Tcf 
consensus binding sites upstream of firefly luciferase cDNA; or FOP-FLASH, 
a plasmid with mutated Tcf binding sites; or their empty vector (pGL3) as 
control (gift from Thomas Clevers) (Upstate Biotechnology) (Chuang KA et al. 
2010). After 24 h, the cells were incubated overnight with PBS-PEG (control) 
or 100μM dipyridamole at 37 °C. After this incubation, the total cell lysates 
were extracted using reporter lysis buffer (Promega) and the luciferase 
activities were determined using the Dual-Glo Luciferase® Assay System 
(Promega) with a microplate Luminometer (Perkin Elmer, EnVision 2102 
Multilabel Reader). Each experimental point was assessed in triplicate, and two 
independent sets of experiments were performed. To assess the dipyridamole 
induced-impairment of NF-kB p65 transcription activity, the cells were then 
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transfected using CaCl2 and 2× HBS reagent with 15 ng Tk-Renilla luciferase 
plasmid, 65 ng of p65 plasmid, or its empty vector (pcDNA3.1) as control, and 
25 ng of a firefly luciferase reporter construct containing the immunoglobulin 
promoter (IgLuc), or its empty vector (pGL3) as control. After 24 h, the cells 
were incubated overnight with PBS-PEG (control) or dipyridamole (10, 100 
μM) at 37 °C. After this incubation, the total cell lysates were extracted using 
reporter lysis buffer (Promega), and the luciferase activities were determined 
using the Dual-Glo Luciferase Assay System. 
 
 
 
4.6 In-vivo mouse experiments 
 
Athymic nude and Balb/c mice were purchased from Harlan. All 
of the animal experiments were conducted according to Italian law. Every 
effort was made to minimize the suffering of the animals, and to minimize the 
number of animals used. Seven-week-old mice were anesthetized with 3% 
avertin (Sigma) solution, and then had 4T1-Luc cells either implanted into the 
VIII right-side mammary gland or injected into the left ventricle of the heart. 
The 4T1-Luc xenograft mice were treated with vehicle (PBS-PEG) or 
dipyridamole (30 or 60 mg/kg/day), for 5 days/week (2 injections/day) for 2-4 
weeks, beginning one or two weeks after implantation/injection. The 
treatments were administered intraperitoneally. At the end of the experiments, 
the primary tumors were dissected out and embedded in paraffin, for 
immunohistochemistry (IHC) analyses. 
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4.7 In-vivo bioluminescence imaging 
 
Cell implantation and tumor growth were monitored by 
bioluminescence imaging (BLI) acquisition using an IVIS 3D Illumina 
Imaging System (Xenogen/Caliper). Briefly, the mice were anesthetized with 
isoflurane, injected intraperitoneally with D-luciferin solution (15 mg/ml stock; 
100 μl per 10g body weight), and imaged. For the intracardiac-injected mice, 
two acquisitions (ventral and dorsal) were made per mouse; while for the 
mammary fat-pad implanted mice, one acquisition (ventral) was made per 
mouse. To quantify the bioluminescence, the integrated fluxes of photons 
(photons per s) within each area of interest were determined using the Living 
Images Software Package 3.2 (Xenogen-Caliper). For each intracardiac-
injected mouse, the ventral and dorsal integrated fluxes of photons were added 
together. According to the time and treatment, the means ±SE of the photon 
integrated fluxes were calculated for each experimental point. 
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5. Results 
 
 
 
 
5.1 Dipyridamole impairs in-vitro cell growth 
 
  
 To assess the dipyridamole ability to impair cell growth, in-vitro 
cell proliferation assays were performed on triple-negative murine 4T1-Luc 
and human MDA-MB-231T breast-cancer cells. Dipyridamole decreased the 
proliferation of both the 4T1-Luc and the MDA-MB-231T cells, in dose- and 
time-dependent manners, as compared to the PBS-PEG–treated (control) cells, 
indeed significantly reduced the proliferation of these cell lines at almost all of 
the experimental points tested (Fig. 5A; 4T1-Luc, p <0.001; MDA-MB-231T p 
<0.035; Students’ t-test). The exception here was 24 h treatment of 4T1-Luc 
cells with 10 μM dipyridamole, as compared to these PBS-PEG–treated cells (p 
= 0.2, Students’ t-test).  
Similar results were obtained in real-time proliferation assays 
using the xCelligence System. 4T1-Luc cells treated with dipyridamole showed 
a progressive significant reduction in increment of CI as compared to the 
vehicle (DMSO) after the first hour of treatment (Fig. 5B). The cell 
proliferation assay on dipyridamole treated MDA-MB-231T cells, showed that 
dipyridamole caused a transient decrease in CI also during the first hours after 
its addition, which was then followed by a significant reduced increase in CI of 
these dipyridamole treated cells, as compared to the vehicle (DMSO)-treated 
cells (Fig. 5C). 
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Figure 5. In-vitro effects of dipyridamole on cell proliferation. (A) Representative 
cell proliferation assay (of two experiments performed with similar results) with 4T1-
Luc and MDA-MB-231T cells treated with PBS-PEG (control) or dipyriramole (as 
indicated). Data are means ±SE. * p<0.001, ** p<0.035 (Students’ t-test). (B, C) 
Representative dynamic monitoring of cell proliferation (each with two experiments 
performed with similar results) of 4T1-Luc (B) and MDA-MB 231T (C) cells treated 
with DMSO (control) or 50 μM dipyridamole (as indicated). Arrows, time of 
vehicle/dipyridamole addition, to which cell index (CI) values were normalized. Data 
are means ±SD. 
 
 
 
 
 
 
 
To unravel the molecular mechanisms involved in this cytostatic 
dipyridamole effect, we analyzed cell-cycle perturbation by dipyridamole. The 
data obtained showed that dipyridamole had significant effects on the cell cycle 
at 50 M of concentration only for the MDA-MB-231T cells, which resulted in 
a 19.3% increase in the G1-phase cell population, as compared to the PBS-
PEG–treated cells (Fig. 6A; p = 0.0013, Students’ t-test). 
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In summary here, dipyridamole inhibited cell proliferation in these two triple-
negative breast-cancer cell lines. 
 
 
 
 
 
Figure 6. Dipyridamole effects on cell cycle. (A) Representative FACS analysis for 
cell-cycle phases (of two experiments performed with similar results) of 4T1-Luc and 
MDA-MB-231T cells treated for 24 h with PBS-PEG or dipyridamole (as indicated). 
Data are means ±SE. * p <0.01 (Students’ t-test). 
 
 
 
 
 
 
5.2 Dipyridamole impairs in-vitro cell motility 
 
 
To determine dipyridamole effects on cell migration, in-vitro 
cell motility assays were performed with these 4T1-Luc and MDA-MB-231T 
triple-negative breast-cancer cell lines. As shown in these results, 50 M and 
100 M dipyridamole significantly impaired 4T1-Luc cell migration in a dose-
dependent manner (Fig. 7A; p=0.039, 0.018, respectively, Students’ t-test). 
Similarly, 100 M dipyridamole treatment almost completely blocked MDA-
MB-231T cell motility (Fig. 7B; p <0.0001, Students’ t-test). 
In summary here, dipyridamole inhibited cell motility of these two triple-
negative breast-cancer cell lines. 
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Figure 7. Dipyridamole effects on cell motility. Representative motility assays (each 
with two experiments performed with similar results) in 4T1-Luc (A) and MDA-MB-
231T (B) cells treated for 4 h with PBS-PEG or dypiridamole (as indicated). Data are 
means ±SE. (A) * p = 0.039, ** p = 0.018. (B) * p <0.0001 (Students’ t-test). 
 
 
 
 
 
 
 
 
5.3 Dipyridamole inhibits key signaling pathways in vitro 
 
 
The strong cytostatic effects of dipyridamole suggested that it 
can affect key signaling pathways in tumors. To identify these signaling 
pathways that are affected by dipyridamole, we analyzed dipyridamole-induced 
perturbations of activation of the Wnt, ERK1/2-MAPK and AKT signaling 
pathways in these 4T1-Luc cells. Initially, the protein levels of β-catenin (a 
major effector of the canonical Wnt pathway), of GSK-3β (which in turn 
phosphorylates β-catenin thus causing its degradation and consequently the 
inhibition of Wnt pathway), Ser 9 phosphorylated GSK-3β (P-GSK-3β; the 
GSK-3β inactivated form) and expression levels of the phosphorylation states 
of ERK1/2 proteins were determined in 4T1-Luc cells after in vitro 
dipyridamole treatment. It also has been analyzed the expression levels of AKT 
and Ser 473 phosphorylated AKT proteins. As shown in the data the treatment 
with dipyridamole reduced the activated β-catenin levels and decreased the P-
GSK-3β/GSK-3β ratio, thus determining in an increased activation of GSK-3β 
kinase activity, then resulting in an impairment of Wnt signaling, indeed 
significant reductions of phospho-ERK1/ERK1 (P-ERK1/ERK1) and phospho-
ERK2/ERK2 (P-ERK2/ERK2) ratios were observed in 4T1-Luc cells after in 
vitro 100 M dipyridamole treatment as compared to PBS-PEG–treated cells, 
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thus resulting in an impairment of ERK1/2-MAPK and Wnt pathways 
activation (Fig.8 A-B; P-ERK1/ERK1 p = 0.017; P-ERK2/ERK2 p = 0.047; 
Students’ t test). No change in P-AKT/AKT ratio was observed in 4T1 Luc 
cells after in vitro dipyridamole treatment, which overall thus indicates that 
dipyridamole does not alter the activation of this signaling pathway (Fig. 8A-
B). 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Dipyridamole impairs Wnt and ERK1/2-MAPK signaling pathways in 
vitro. (A) Immunoblotting for phospho-AKT, AKT, phospho-ERK1/2, ERK1/2, 
phospho-GSK-3b, GSK-3b, total and activated b-catenin in 4T1-Luc cells treated for 
4h with PBS-PEG or dipyridamole (as indicated). β-actin used as control for equal 
loading. (B) The densitometer analyses for the proteins from A. Data are mean ± SE. 
*P-ERK1/ERK1 p = 0.017; P-ERK2/ERK2 p = 0.047(Students’ t test). 
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To further verify this dipyridamole impairment of the Wnt 
signaling pathway, we transiently transfected HEK293T cells with the 
TOP/FOP-FLASH system (Figure 9A), which allows the detection of β-catenin 
transcriptional activation by measuring luciferase reporter activity. After 
transfection, these cells were treated with PBS-PEG (control) and 
dipyridamole, and their luciferase activities were measured. As shown in 
Figure 9B, in absence of the plasmid encoding β-catenin, the HEK293T cells 
transfected with the empty vector (pGL3) and with each of the plasmids of the 
TOP/FOP-FLASH system showed a very low level of normalized firefly 
luciferase activity. In the presence of the plasmid encoding β-catenin an 
increased level of normalized firefly luciferase activity was observed in those 
cells transfected with the TOP-FLASH plasmid containing four Tcf consensus 
binding sites upstream of firefly luciferase cDNA. As expected, the normalized 
firefly luciferase activity did not increase in those cells transfected with FOP-
FLASH plasmid with mutated Tcf binding sites or with pGL3 vector. The 
dipyridamole treatment of HEK293T cells cotrasfected with the plasmid 
encoding β-catenin and with the TOP-FLASH plasmid determined a significant 
reduction of the normalized firefly luciferase activity as compared to the 
control cells (Fig. 9B; p = 0.006, Students’ t-test). 
We then investigated this dipyridamole-induced Wnt pathway 
attenuation in terms of the expression of some targets of the Wnt signaling, the 
CD49f, cyclin D1, survivin and c-Myc proteins (Vlad et al. 2008). As shown in 
the results, dipyridamole significantly decreased the percentage of 4T1-Luc 
breast-cancer cells that expressed the membrane antigen CD49f (Fig. 9C; p = 
0.008, Students’ t-test). At the same time, in the MDA-MB-231T cells, 
dipyridamole significantly decreased the expression levels of the cyclin D1, 
survivin and c-Myc proteins (Fig. 9D). 
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Figure 9. Dipyridamole reduces the transcriptional activation of b-catenin and 
expression of Wnt target genes. (A-B) Representative luciferase activity in 
TOP/FOP FLASH system transfected HEK293T cells (of two experiments performed 
with similar results) after overnight treatment with PBS-PEG or dipyridamole (as 
indicated). Data are mean ± SE. *p = 0.006 (Students’ t test). (C) Representative 
analysis for percentage positivity to CD49f, a known target of Wnt pathway (of two 
experiments performed with similar results) of 4T1-Luc cells treated for 24 h with 
PBS-PEG or dipyridamole (as indicated). Data are mean ± SE. *p = 0.008 (Students’ t 
test).(D) Immunoblotting for c-Myc and survivin in MDA-MB 231T cells treated for 
24 h with PBS-PEG or dipyridamole (as indicated). β-actin used as control for equal 
loading. 
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Previous reports have shown that dipyridamole attenuates 
activation of the NF-kB signaling pathway (Chakrabarti S, et al. 2007, Weyrich 
AS et al. 2005). Therefore, we investigated whether this was also the case in 
the 4T1-Luc breast cancer cells, by determination of the expression levels of 
IkBα, an inhibitor of the NF-kB signaling pathway. Here, 4 h of in-vitro 
dipyridamole treatment of the 4T1-Luc cells at both 10 µM and 100 µM did 
not alter the IkBα level. However, 24 h of treatment with 100 µM dipyridamole 
resulted in the up-regulation of IkBα (Fig. 10A), thus indicating dipyridamole-
induced attenuation of the NF-kB signaling pathway. 
To further address this point, the expression levels of phosphorylated IkBa (P-
IkBa), p65 and phosphorylated p65 (P-p65) proteins were determined by 
western blotting analyses (Fig. 10A). As shown in figure 10B, a reduction of 
both the P-IkBa/IkBa and P-p65/p65 ratios that reached the limit of 
significance was observed at 100 M dipyridamole (p = 0.06, p = 0.077 
respectively, Students’t test), which thus further suggests dipyridamole-
induced attenuation of NF-kB signaling pathway. We then transiently 
cotransfected HEK293T cells with a plasmid encoding p65 and a plasmid 
containing the immunoglobulin promoter, which is responsive to p65, upstream 
of firefly luciferase cDNA (IgLuc vector). After transfection, these cells were 
treated with PBS-PEG (control-vehicle) and dipyridamole, and their luciferase 
activities were measured. As shown in figure 10C, in absence of the plasmid 
encoding p65 the HEK293T cells transfected with the empty vector (pGL3) 
and with IgLuc plasmid showed a low level of normalized firefly luciferase 
activity. In the presence of the plasmid encoding p65 an increased level of 
normalized firefly luciferase activity was observed in only those cells 
transfected with the IgLuc plasmid. As expected, the normalized firefly 
luciferase activity did not increase in those cells transfected with pGL3 vector, 
thus further confirming the specificity of responsiveness of immunoglobulin 
promoter within our in vitro assay. 
At this time, we found that the dipyridamole treatment of HEK293T cells 
cotransfected with the plasmid encoding p65 and with Ig-Luc plasmid induced 
less of an increase in the normalized firefly luciferase activity as compared to 
the control transfected cells (Fig. 10C; 10 μM dipyridamole p = 0.04; 100 μM 
dipyridamole p = 0.003; Students’ t test). 
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Figure 10. Dipyridamole impairs NF-kB signaling pathway in vitro. (A) 
Immunoblotting for phospho-IkBa, IkBa, phospho-p65 and p65 in 4T1-Luc cells 
treated for 24 h with PBS-PEG or dipyridamole (as indicated). β-actin used as control 
for equal loading. (B) The densitometry analyses for the proteins from A. Data are 
mean ± SE. (C) Representative luciferase activity in p65 and IgLuc transfected 
HEK293T cells (of two experiments performed with similar results) after overnight 
treatment with PBS-PEG or dipyridamole (as indicated). Data are mean ± SE. *10 μM 
dipyridamole p = 0.04; 100 μM dipyridamole p = 0.003 (Students’ t test). 
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5.4 Dipyridamole impairs in-vivo primary tumor growth 
 
 
The action of dipyridamole was further investigated in an in-
vivo 4T1-Luc breast-cancer xenograft mouse model. 
To determine the effects of dipyridamole on primary tumor growth, the 4T1-
Luc cells were orthotopically implanted into the mammary fat pads of Balb/c 
syngeneic mice. In the first set of experiments, 5×10
4
 4T1-Luc cells were 
implanted. Vehicle (PBS-PEG control) or dipyridamole (15 or 30 mg/kg/day 
for 5 days/week) were administered intraperitoneally beginning on day 7 post 
implantation. Both of these dipyridamole treatments showed significant 
reductions in the primary tumor volume compared to the PBS-PEG control 
mice. At the 15 mg/kg/day dose, dipyridamole inhibited the mean tumor size 
on day 21 post-implantation by 67.5%, as compared to the control (p = 0.0433, 
ANOVA). At the higher, 30 mg/kg/day, dipyridamole dose, there was 
essentially no tumor growth in the dipyridamole-treated animals (p = 0.0182, 
ANOVA). 
To confirm these data, the number of cells implanted into the 
mammary fat pad of these Balb/c syngeneic mice was increased (by 5-fold, to 
2.5×10
5
 4T1-Luc cells) and the beginning of the vehicle and dipyridamole 
treatments was delayed to day 14 post-implantation. At this stage, the mean 
tumor size according to the BLI measurements was at least one order of 
magnitude greater than the primary tumors treated in the initial experiments 
here. At the same time, the intraperitoneal dipyridamole treatment was 
increased to 60 mg/kg/day (5 days/week). Figure 11A shows representative 
images of these PBS-PEG control and dipyridamole-treated mice following the 
4T1-Luc cell implantation (day 0) and at 42 days post-implantation. Overall, 
the mice treated with dipyridamole showed a significant 76.7% reduction in 
tumor volume on day 42 post-implantation, as compared to the controls (Fig. 
11A; p = 0.0429, ANOVA). 
To further demonstrate this dipyridamole impairment of primary 
tumor growth, the levels of Ki67, a marker of tumor-cell proliferation, were 
assessed by IHC on sections from the tumors of these vehicle- and 
dipyridamole-treated mice. Representative images of this Ki67 staining are 
shown in figure 11B, while the quantification shown in figure 11C illustrates 
that overall, the percentage of Ki67-positive tumor cells was significantly 
reduced by 19.7% in tumors from dipyridamole treated mice as compared to 
those from the control mice (p = 0.0032, ANOVA).  
In summary here, intraperitoneally delivered dipyridamole inhibited in-vivo 
4T1-Luc primary tumor growth over a range of inocula. 
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Figure 11. Dipyridamole impairs primary tumor growth. (A) On the left: 
representative bioluminescent images of mice implanted with 4T1-Luc cells in the 
mammary fat pad at day 0 and 42 days after intraperitoneally administered treatments 
with vehicle and 60 mg/kg/day dipyridamole (i.e. 4 weeks treatment). On the right: 
time-course of bioluminescent signals from 4T1-Luc tumor cells implanted into mouse 
mammary fat pad at day 0, followed by intraperitoneally administered treatments with 
vehicle and 60 mg/kg/ day dipyridamole started on day 14. Data are total flux mean ± 
SE. *p = 0.0429 (ANOVA). (B) Representative images of Ki67 IHC in sections of 
4T1-Luc primary tumors from A. (C) Percentages of Ki67 positive tumor cells nuclei 
in sections of 4T1-Luc primary tumors from A. Data are mean ± SEM. p = 0.0032 
(ANOVA). 
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5.5 Dipyridamole impairs key signaling pathway in vivo 
 
 
We also investigated the in-vivo ability of dipyridamole to 
impair the Wnt, ERK1/2-MAPK and NF-kB signaling pathways. Here, the 
percentages of tumor cells positive for activated β-catenin, phospho-ERK1/2, 
phospho-p65 (Ser-311) (the activated form of p65, that translocates into the 
nucleus and actives the transcription of target genes) and IkBα (the inhibitor of 
NF-kB pathway) were evaluated on tumor sections by IHC. Representative 
images of this staining are shown in figure 12A. In the 4T1-Luc mammary fat-
pad mouse xenograft model, the percentage of activated β-catenin-positive 
tumor cells was significantly reduced by 38.6% in tumors from the 
dipyridamole treated mice, as compared to those from the vehicle-treated mice 
(Fig. 12B; p <0.0001, ANOVA). Additionally we evaluated in vivo the 
phospho-ERK1/2 inhibition as already encountered in vitro. Representative 
images of phospho-ERK1/2 staining are shown in figure 12A. In the 4T1-Luc 
mammary fat-pad mouse xenograft model, the percentage of phospho ERK1/2–
positive tumor cells nuclei was significantly reduced by 6.4 % in tumors from 
the dipyridamole-treated mice, as compared to those from the vehicle-treated 
mice (Fig. 12B; p = 0.0187, ANOVA). 
Then we investigated in vivo the NF-kB pathway by measuring 
the number of IkB-positive tumor cells in those treated animals. For IkB 
(whose representative images are shown in figure 12A), in the 4T1-Luc 
mammary fat-pad xenograft model, the intraperitoneally administered 
dipyridamole doubled the percentages of IkB-positive tumor cells (Fig. 12B; 
p = 0.0487). According to the results for IkB, in the 4T1-Luc mammary fat-
pad mouse xenograft model, the percentage of phospho-p65-positive tumor 
cells nuclei (whose representative images are shown in figure 12A) was 
significantly reduced by 67.82 % in tumors from the dipyridamole-treated 
mice, as compared to those from the vehicle-treated mice (Fig. 12B; p <0.0001, 
ANOVA).  
In summary here, dipyridamole-induced inhibition of the Wnt, ERK1/2-MAPK 
and NF-kB signaling pathways was seen in in-vivo primary tumorigenesis. 
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Figure 12. Dipyridamole impairs signaling pathways in vivo. (A) Representative 
images of activated β-catenin, IkB, phospho-p65 (Ser 311) and phospho-ERK1/2 
IHC in sections of 4T1-Luc primary tumors from mice treated with intraperitoneally 
administered PBS-PEG or dipyridamole (as indicated). (B) Percentages of activated β-
catenin, IkB, phospho-p65 (Ser 311) and phospho-ERK1/2 positive tumor cells 
nuclei in sections of 4T1-Luc primary tumors from mice treated with intraperitoneally 
administered vehicle or dipyridamole (as indicated). Data are mean ± SEM with a 
value that reach statistical significance (p <0.0001, p=0,0487, p <0.0001 and p 
=0,0187 respectively) (ANOVA).  
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5.6 Dipyridamole impairs the tumor microenvironment 
 
 
 
The NF-kB pathway is critical for both the tumor cells and the 
inflammatory cells in the tumor microenvironment. To determine the effects of 
dipyridamole treatment on immune-cells infiltration into the tumor 
microenvironment, IHC analyses of TAMs and MDSCs were conducted on 
sections of primary tumors from the breast cancer xenograft mice implanted 
with 4T1-Luc cells into the mammary fat pad that had been treated with 
vehicle (PBS-PEG) or 60 mg/kg/day dipyridamole (5 days per week). 
Representative images of this staining are shown in figure 13A. For both the 
MDSCs (CD11b+ and Gr1+ cells) (Fig. 13A-B) and TAMs (CD163+ and CD68+ 
cells) (Fig. 13A-B), infiltration into the tumor microenvironment was 
significantly decreased by dipyridamole treatment, as compared to vehicle 
treatment (Gr1, p = 0.0042; other markers, p <0.0001, ANOVA). 
In addition, the NF-kB signaling pathway regulates cytokines 
production in inflammatory cells. Based on these data, we further asked 
whether this dipyridamole treatment can influence the serum levels of the 
cytokines in this breast-cancer xenograft mouse model. Here, the 60 mg/kg/day 
(5 days per week) dipyridamole treatment of the xenograft mice implanted with 
4T1-Luc cells into the mammary fat pad significantly reduced the serum levels 
of IL-1β, MIP-1a and SCF, as compared to the vehicle treatment (Fig. 13C; p = 
0.01, p = 0.03, p = 0.03, respectively, Students’ ttest), with similar trends seen 
for other cytokines tested (Fig. 13C; IL-1, G-CSF, GM-CSF). 
Therefore, dipyridamole has in-vivo effects on the NF-kB pathway in both 
tumor cells and the tumor microenvironment, which result in negative 
regulation of the inflammatory response. 
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Figure 13. Dipyridamole impairs tumor microenvironment and serum 
inflammatory cytokine levels. (A) Representative images of CD11b, Gr1, CD163 
and CD68 IHC in sections of 4T1-Luc primary tumors from mice treated with 
intraperitoneally administered PBS-PEG or dipyridamole (as indicated). (B) 
Percentage of cells positive to CD11b, Gr1, CD163 and CD68 in sections of 4T1-Luc 
primary tumors. Data are mean ± SEM. p <0.0001; p = 0.0042; p = 0.0007; p <0.0001 
(ANOVA) respectively. Absorbances for serum cytokine levels from 4T1-Luc cell 
implanted mice treated with PBS-PEG or dipyridamole (as indicated). Data are mean 
± SE. * IL-1, p = 0.01; MIP-1a, p = 0.03; SCF, p = 0.03 (Students’ t test). 
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5.7 Dipyridamole impairs in vivo metastasis 
 
 
To determine the effects of dipyridamole on metastasis foci 
formation and growth, experimental metastasis assays were conducted using 
the 4T1-Luc cells. The 4T1-Luc cells were injected into the arterial circulation 
via the left cardiac ventricle of Balb/c syngeneic mice. The vehicle (PBS-PEG 
control) and the dipyridamole (30 mg/kg/day for 5 days/week) were 
administered intraperitoneally beginning on day 7 post injection, at which time 
a few metastatic foci were detected by bioluminescence imaging (BLI).  
The BLI acquisition images of mice on the day of injection (day 0) and at week 
3 post-injection (2 weeks of treatment) showed widespread metastatic 
involvement in the control mice, and visibly fewer and smaller metastatic foci 
in the dipyridamole-treated mice (Fig.14A-B). The overall BLI data analysis 
showed that the total flux per mouse was decreased by 50.3 % in the 
dipyridamole treated mice, as compared to the vehicle treated mice. The 
therapeutic efficacy of dipyridamole in metastasis treatment is suggested by its 
efficacy to inhibit metastasis formation in this 4T1-Luc breast-cancer mouse 
xenograft model, in which the treatment was delayed to day 7 after tumor-cell 
injection, when a few metastatic foci could already be detected (Fig.14A-B). 
In this mouse experiment, there were neither behavioral changes nor weight 
loss due to drug toxicity in the dipyridamole-treated mice, as compared to the 
control mice. 
 
 
 
Figure 14. Dipyridamole impairs in vivo metastasis formation (A) Representative 
bioluminescent images of mice intracardiacally injected with 4T1-Luc cells at day 0 
and at week 3, after week 1 treatments with vehicle and 30 mg/kg/day dipyridamole 
intraperitoneally were administered (i.e. 2 weeks treatment). Ventral and dorsal 
photographs were taken for each mouse. (B) Time-course of bioluminescent signals 
(of two experiments performed with similar results) from mice injected 
intracardiacally with 4T1-Luc tumor cells. Data are total flux mean ± SE. *p = 0.0292, 
ANOVA. 
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6. Discussion 
 
 
 
 
In current therapeutic practice, dipyridamole is rarely used as a 
single agent. However, an extended-released form of dipyridamole (Persantin 
Retard 200 mg) in combination with aspirin (25 mg) has been designed to take 
advantage of the additive antiplatelet effects of both of these agents, and this 
combination is used for secondary stroke prevention (White H and Jamieson 
DG 2010). Based on the in vitro evidence that dipyridamole can modulate the 
cytotoxicity of a variety of antitumor agents (Howell SB et al. 1989), phase I 
and phase II clinical trials of the combination of dipyridamole and cytotoxic 
agents were performed in patients with advanced refractory malignancy (Budd 
GT et al. 1990, Chakravarthy A et al. 2000). Unfortunately, in these clinical 
trials, there were disappointing results in terms of the shrinkage of the 
established refractory metastases. In the present study, we have demonstrated 
strong cytostatic and motility inhibitory effects of single-agent dipyridamole in 
vitro, with the concomitant reduction of primary tumor growth and metastasis 
formation in vivo.  
These conflicting results appear to be attributed to the mode of drug delivery. 
Indeed, previous studies showed that, depending upon the mode of delivery, a 
broad range of free dipyridamole concentrations is achieved with the 
intraperitoneal infusion more efficient than oral administration or intravenous 
infusion (Willson JK et al 1988, Goel R et al. 1989, Isonishi S et al. 1991). 
Based on these data, it is probable that the limited success of dipyridamole in 
the previous clinical trials can be ascribed to its delivery mode (oral 
administration or intravenous infusion) (Budd GT et al. 1990, Chakravarthy A 
et al. 2000). Based on our data, we propose that dipyridamole can be used in 
the clinic both as a therapeutic agent for the treatment of triple-negative breast-
cancer primary tumors and as therapeutic agent for the treatment of triple-
negative breast-cancer metastasis. Translation of these data into the clinic 
awaits further pharmacokinetic studies. Another limitation to the clinical 
application of dipyridamole has been its extensive binding to the serum protein 
a1 acid glycoprotein (AGP) (Mahony C et al.1982), an acute-phase protein that 
is elevated in the plasma of cancer patients. 
The avid binding of dipyridamole to AGP decreases the free 
plasma concentrations of dipyridamole to levels that are insufficient for its 
therapeutic effects (Curtin NJ et al. 1999). Recently, a liposome-based 
intravenous delivery strategy of dipyridamole in combination with perifosine 
was used for inhibition of metastasis in a breast-cancer xenograft model 
(Wenzel J et al. 2009). This approach thus has the potential to be applied to 
clinical trials in humans, to improve the distribution and delivery of 
dipyridamole, and to prevent the binding of dipyridamole to AGP. Additional 
studies will be required to address the dipyridamole delivery mode 
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(intraperitoneal or intravenous delivery by liposomes) and to refine a proposed 
dose and schedule for dipyridamole treatment that can be included in a clinical 
trial.  
Several molecular mechanisms might be responsible for the in 
vivo therapeutic efficacy of dipyridamole. A few insights on molecular 
mechanisms by which dipyridamole inhibits cell proliferation were provided 
by Goda and collaborators (Goda AE, et al. 2008), who described a novel 
mechanism of dipyridamole induced G1 arrest in human osteosarcoma and 
prostate carcinoma cells. In this study we further confirm the dipyridamole 
induces in vitro G1 cell cycle arrest in breast cancer cells and provide evidence 
that dipyridamole impairs in vivo the breast cancer tumor growth and 
metastasis formation in 4T1-Luc breast cancer xenograft models. In an effort to 
further unravel the molecular mechanism of dipyridamole-induced 
proliferation inhibition we examined the signaling pathways perturbation by 
dipyridamole. Previous data have established that dipyridamole can attenuate 
the NF-kB signaling pathway (Weyrich AS et al. 2005). In the present study, 
we also provide evidence that both in vitro and in vivo, dipyridamole can 
attenuate the Wnt signaling pathway, through reduced β-catenin activation, 
ERK1/2-MAPK signaling pathway, through the reduced phosphorylation of 
ERK1/2, and the NF-kB signaling pathway, through increased IkBa expression 
levels, decreased phosphorylation of p65 and reduced inflammatory cytokines 
systemic production (including IL-1β, which is activated by NF-kB with an 
activation feedback loop). As all of these signaling pathways promote cell 
proliferation, their dipyridamole-induced attenuation might represent a 
molecular mechanism by which dipyridamole can reduce tumor growth. 
Literature data provides evidence of ERK1/2-MAPK signaling in cell 
migration (Huang C,et al.2004). Therefore, the ability of dipyridamole to 
impair cell motility and metastasis process might be due to its inhibitory effects 
on the ERK1/2-MAPK signaling pathway. Signaling systems feature extensive 
crosstalk, and thereby form a complex network of interactions. Several 
previous studies have also shown that Wnt and NF-kB pathways are linked to 
each other by a positive-feedback loop. Kaler and collaborators described IL-
1β as an activator of the Wnt signaling pathway that acts in a NF-kB-dependent 
manner (Kaler P et al. 2009). This suggests that in vivo, the dipyridamole-
induced Wnt pathway attenuation can be further enhanced by decreased IL-1β 
expression due to the impairment of the NF-kB signaling pathway. A crosstalk 
with a positive-feedback loop between the Wnt and ERK pathways has been 
identified in tumor cells (Kim D et al. 2007). The activated ERK induces GSK-
3β inhibition, which stops β-catenin degradation leading to its accumulation 
and translocation into the nucleus where β-catenin forms a complex with TCF. 
The β-catenin/TCF complex enhances the expression or activation of the 
unknown crosstalk molecules which then activates ERK via stimulation of Raf-
1 and MEK, thus further perpetuating the activation loop. Interestingly, a 
crosstalk between ERK1/2-MAPK signaling and NF-kB pathway was already 
identified, in which ERK targets IKKα that in turn phosphorylates IkBα, thus 
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activating NF-kB signaling pathway (Chuderland D and Seger R 2005). 
Although the data here presented show that dipyridamole inhibits Wnt, 
ERK1/2-MAPK and NF-kB pathways, at this time it is not possible to 
determine whether dipyridamole directly affects at the same time on all of 
those pathways. Indeed the extensive crosstalk between these pathways opens 
the possibility that dipyridamole might target only one or two of these 
pathways with consequences on the other(s). The positive-feedback loop 
between Wnt and ERK pathways strength this hypothesis. Moreover, our data 
show that in vitro dipyridamole treatment for 4h inhibits Wnt and ERK1/2- 
MAPK pathways, but does not impair the NF-kB pathway, which is then 
affected only 24 h later during the treatment. This could lead to the hypothesis 
that inhibition of NF-kB is an indirect consequence of the action of 
dipyridamole on the previous two affected pathways. Further studies performed 
with specific inhibitors of these and other pathways are needed to address this 
question, thus dissecting further the mechanism of dipyridamole action. 
Another molecular mechanism, by which dipyridamole might exert its in vivo 
therapeutic effects is through the impairment of TAMs and MDSCs infiltration. 
Within the tumor microenvironment, both TAMs and MDSCs have pro-
tumoral functions, which thus promote tumor-cell survival and proliferation, 
along with angiogenesis, incessant matrix turnover, dissemination and 
repression of adaptive immunity (Curtin NJ et al.. 1999, Huang C et al. 2004). 
Therefore, attenuation of the infiltration of these immune cells might result in 
reductions in tumor growth and invasiveness. 
Biochemical studies have also identified the transcription factor 
NF-kB as a master regulator of cancer-related inflammation in TAMs and in 
neoplastic cells. Constitutive NF-kB activation is indeed often seen in cancer 
cells, and this might be promoted by cytokines (e.g., IL-1β and TNFα) 
expressed by TAMs or other stromal cells, as well as by environmental cues 
(e.g., hypoxia and reactive oxygen intermediates) or by genetic alterations. NF-
kB induces several cellular modifications associated with tumorigenesis and 
with more aggressive phenotypes, which include self-sufficiency in growth 
signals, insensitivity to growth inhibition, resistance to apoptotic signals, 
angiogenesis, and cell migration and tissue invasion (Kim D et al. 2007). 
Therefore, this ability for dipyridamole to affect the tumor microenvironment 
might be due to its inhibitory effects on the NF-kB signaling pathway. The 
agreement between our in vitro and in vivo data strengthens the evidence that 
the Wnt and NF-kB signaling pathways are potentially mechanistically 
involved, which can be further evaluated in future molecular studies. 
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7. Conclusions 
 
 
 
In conclusion, the present study provides further insights into 
the molecular mechanisms of dipyridamole action, showing its ability to inhibit 
triple-negative breast-cancer primary tumor growth and metastasis formation. 
Moreover, our data document the ability of dipyridamole to decrease the 
activation of the Wnt, ERK1/2-MAPK and NF-kB signaling pathways.  
Finally, we have also described new biological functions of 
dipyridamole, showing its attenuation of immune inflammatory cell infiltration, 
which thus interferes with primary tumor growth and metastatic niche 
formation. We suggest that with appropriate doses and the correct mode of 
administration, dipyridamole is a promising agent for treatment of primary and 
metastatic breast cancer, thus already also implying its potential use in other 
cancers that show highly activated Wnt, ERK1/2-MAPK and NF-kB signaling 
pathways. 
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8. Novelties 
 
 
Dipyridamole is a not toxic and widely used drug in current 
therapeutic practice as a vasodilator for treatment of ischemic disorders (White 
H, Jamieson DG 2010). Additionally, a patent deposited in the EU 
(EP1733729, 2006) shows dipyridamole in combination with acetyl salicylic 
acid and angiotensin II antagonist for stroke prevention. In this study we 
provide evidence for the potential use of dipyridamole in treatment of triple- 
negative breast-cancer patients. For the first time, here, we report that 
dipyridamole is able to impair Wnt and ERK1/2-MAPK signalling pathways 
and confirm, as previously shown by Weyrich and collaborators (Weyrich AS 
et al. 2005) that have the capacity to attenuate NF-kB signaling pathway in 
implemented xenograft animal models of triple-negative breast-cancer.  
Wnt and ERK1/2-MAPK signaling pathways promote tumor growth, 
metastasis and stemness, while NF-kB is an important player in cancer-related 
inflammation. We, for the first time additionally found that dipyridamole 
inhibited the pre-metastatic niche formation and significantly decreased the 
infiltration of tumor-associated macrophages and the myeloid-derived 
suppressor cells in the tumors from treated mice, components of tumor 
microenvironment related to progression of breast cancers. Based on the in 
vitro evidence that dipyridamole can modulate the cytotoxicity of a variety of 
antitumor agents, phase I and phase II clinical trials of the combination of 
dipyridamole and cytotoxic agents were performed in patients with advanced 
refractory malignancy (Budd G.T. et al. 1990). 
Hejna and colleagues (Hejna M  et al. 1999) reported several in vivo trials in 
which dipyridamole was used in treatments of advanced colon-cancer, non 
small cells lung carcinoma and head and neck cancer. There are no evidences 
of therapeutic advantages using dipyridamole with oral administration in 
combination with other drugs, but in our study we assessed the appropriate 
mode of administration of dipyridamole applying the intraperitoneal delivery 
mode which allowed the achievement of drug serum concentrations such as to 
determine the success of the therapeutic trials.  
In light of these novelties we propose dipyridamole as a promising agent in 
clinical treatment of breast cancers and in particular in treatment of triple-
negative breast-cancer patients and its potential use in other cancers in which 
Wnt, ERK1/2-MAPK and NF-kB signaling pathways are over activated and in 
which the role of infiltrating immune cells is determinant for primary tumor 
progression and metastasis development. 
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Abstract Dipyridamole is a widely prescribed drug in
ischemic disorders, and it is here investigated for potential
clinical use as a new treatment for breast cancer. Xenograft
mice bearing triple-negative breast cancer 4T1-Luc or
MDA-MB-231T cells were generated. In these in vivo
models, dipyridamole effects were investigated for primary
tumor growth, metastasis formation, cell cycle, apoptosis,
signaling pathways, immune cell infiltration, and serum
inflammatory cytokines levels. Dipyridamole significantly
reduced primary tumor growth and metastasis formation by
intraperitoneal administration. Treatment with 15 mg/kg/day
dipyridamole reduced mean primary tumor size by 67.5 %
(p = 0.0433), while treatment with 30 mg/kg/day dipyrid-
amole resulted in an almost a total reduction in primary
tumors (p = 0.0182). Experimental metastasis assays show
dipyridamole reduces metastasis formation by 47.5 % in the
MDA-MB-231T xenograft model (p = 0.0122), and by
50.26 % in the 4T1-Luc xenograft model (p = 0.0292).
In vivo dipyridamole decreased activated b-catenin by
38.64 % (p \ 0.0001), phospho-ERK1/2 by 25.05 % (p =
0.0129), phospho-p65 by 67.82 % (p \ 0.0001) and doubled
the expression of IkBa (p = 0.0019), thus revealing signif-
icant effects on Wnt, ERK1/2-MAPK and NF-kB pathways
in both animal models. Moreover dipyridamole significantly
decreased the infiltration of tumor-associated macrophages
and myeloid-derived suppressor cells in primary tumors
(p \ 0.005), and the inflammatory cytokines levels in the
sera of the treated mice. We suggest that when used at
appropriate doses and with the correct mode of administra-
tion, dipyridamole is a promising agent for breast-cancer
treatment, thus also implying its potential use in other can-
cers that show those highly activated pathways.
Keywords Dipyridamole  Metastasis  ERK1/2-MAPK 
Wnt  NF-kB  Immune cell infiltration  Tumor
microenvironment
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Introduction
Despite many advances in the treatment of breast cancer,
worldwide, over 450,000 women die annually of this disease
[1], with tumor metastasis the major cause of these deaths
[2]. Therefore, agents that can prevent metastatic coloniza-
tion of breast tumor cells represent an essential advance in
the therapeutics of this disease. Herein, we identify a novel
role for dipyridamole, a drug already approved by the US
Food and Drug Administration and the European Union, as
an inhibitor of breast-cancer progression.
Dipyridamole is a potent competitive inhibitor of
equilibrative nucleoside transport [3]. The salvage of
extracellular nucleosides and nucleobases via this transport
system results in repletion of the nucleotide pools [4] and
constitutes one of a number of mechanisms by which
tumors resist antimetabolite drugs [5]. Several studies have
shown that in vitro, dipyridamole can significantly increase
the cytotoxic and antitumor activities of a variety of che-
motherapeutic agents [6–12]. The underlying mechanism
here is both prevention of nucleoside and nucleobase sal-
vage, and an increase in the intracellular accumulation of
the toxic metabolites [6, 10–14]. Dipyridamole has also
been shown to enhance in vitro TRAIL tumoricidal activity
[15]. Furthermore, it is an effective inhibitor of the
human breast-cancer-resistance protein BCRP/ABCG2
[16], which is a drug efflux transporter, and which confers
resistance to a large number of chemotherapeutic agents by
enhancing the drug efflux [17].
Most importantly, the relationship between dipyrid-
amole and cancer is further emphasized by the anti-platelet
aggregation property of dipyridamole [18]. Due to these
properties, dipyridamole is currently used in the clinic in
combination with aspirin as a vasodilator for ischemic
disorders [19]. To date, there is evidence for a contribution
of platelets in metastasis formation. Platelets are known to
interact with tumor cells to form aggregates, which can
enhance tumor-cell arrest in the vasculature, thus releasing
growth factors and preventing immune attack [20]. Based
on these observations it is not surprising that anti-coagu-
lants and agents that interfere with platelet aggregation,
such as anti-thrombins, can prevent tumor metastases [21].
The clinic potential of dipyridamole for the treatment of
metastasis in human cancers has been tested previously in
combination with several cytotoxic drugs [22–24]. Fur-
thermore, recently, the clinic exploitation of dipyridamole
in combination with perifosine for metastasis treatment in
breast-cancer xenograft animal models has been investi-
gated [25, 26]. These studies, in which dipyridamole was
used in combination with cytotoxic drugs, make the eval-
uation of the clinic potential of dipyridamole for cancer
treatment more difficult.
We have here investigated the potential role of
dipyridamole as a single agent in the prevention of
tumorigenesis and metastasis in multiple models of triple-
negative (estrogen and progesterone receptor-negative,
Her-2 normal) breast cancers, a subtype that has few
effective therapies [27]. Our findings provide evidence that
intraperitoneal administration of dipyridamole impairs
primary tumor growth and metastasis in breast-cancer
xenograft animal models. Moreover, our data identify new
mechanisms of action of dipyridamole, which is shown to
inhibit the ERK1/2-MAPK, NF-kB and Wnt signaling
pathways, and to prevent the accumulation of inflammatory
cells in the tumor microenvironment. These data suggest
that this safe, already approved agent might have a new use
in appropriately designed clinical trials.
Materials and methods
Drug preparation
Persantin Retard modified-release capsules containing
200 mg dipyridamole (B01AC07; Boehringer Ingelheim)
were dissolved at 6 mM concentration in PBS-PEG (phos-
phate-buffered saline-polyethylene glycol 400 (Sigma))
(v/v) or in dimethylsulfoxide (DMSO). After dipyridamole
was dissolved in PBS-PEG, the solution was sterilized by
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passing it through a 0.22 lm filter. The dipyridamole solu-
tion in DMSO was used in the proliferation assays in real-
time using the xCelligence system. In all of the other
experiments the dipyridamole solution in PBS-PEG was
used.
Cell culture
Triple-negative murine 4T1-Luc and human MDA-MB-
231T breast-cancer cell lines were used for the in vitro and
in vivo experiments. 4T1-Luc cells were used for in vivo
implantation into the mammary fat pad and for metastasis
experiments. MDA-MB-231T cells were used for in vivo
lung-metastasis experiments. HEK293T cells were used for
the luciferase reporter assay. All of these cells were grown
in high-glucose Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen) supplemented with 10 % (v/v) fetal
bovine serum (Invitrogen), 2 mM L-glutamine (Invitro-
gen), and 1 % (v/v) antibiotics (10000 U/ml penicillin,
10 mg/ml streptomycin [Invitrogen]). The cells were
grown at 37 C in a humidified atmosphere of 95 % air,
5 % CO2 (v/v).
Proliferation assay
Proliferation assays were performed using the CellTiter 96
Aqueous One Solution Cell Proliferation Assay (Promega).
The 4T1-Luc cells (2 9 103/well) and MDA-MB-231T
cells (3 9 103/well) were plated into 96-well plates and
treated with PBS-PEG (control) or PBS-PEG containing
10, 50 or 100 lM dipyridamole, for 0, 24, 48 and 72 h.
Each experimental point was assessed in quadruplicate.
The medium supplemented with PBS-PEG or dipyridamole
was replaced twice daily. For each experimental point,
20 ll (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) solution
(1.90 mg/ml) was added to each well, and the cells were
incubated for 2 h at 37 C. Absorbance was then measured
at 490 nm using a microtitre plate reader (VICTOR3 1420
Multilabel Counter, Perkin Elmer). For each experimental
point, the means of absorbance and their standard errors
(SE) were calculated. A total of two independent sets of
experiments were performed.
Flow cytometry
The 4T1-Luc and MDA-MB-231T cells were treated with
PBS-PEG (control) or dipyridamole (10, 50, 100 lM) for
24 h. The medium supplemented with PBS-PEG or dipy-
ridamole was replaced twice daily.
For the cell-cycle analysis, after treatment, the cells
were resuspended in PBS containing 0.002 % Nonidet P40,
12.5 lg/ml ribonuclease A, and 20 lg/ml propidium
iodide, incubated at room temperature for 3 h in the dark,
and analyzed on a FACScan flow cytometer (Becton–
Dickinson Immunocytometry Systems). For each experi-
mental point, the cell-cycle analysis was performed in
triplicate. For each experimental point, the means of
percent cell population in cell cycle phases ±SE were
calculated. Two independent sets of experiments were
performed.
For the evaluation of the percentages of Annexin-V-
positive cells, after 24 h treatment, 2 9 105 4T1-Luc and
MDA-MB-231T cells were incubated for 30 min with a
FITC-conjugated anti-Annexin V antibody (BD Pharmin-
gen) and analyzed using a BD FACSCanto II flow
cytometer (BD Biosciences, Oxford, UK). The collected
data were analyzed using the FACSDiva software, version
6 (BD Biosciences). Each experimental point was assessed
in duplicate. For each experimental point, the means of
percent cell population ±SE were calculated. Two inde-
pendent sets of experiments were performed.
For the evaluation of the percentages of CD49f? cells,
after treatment, 2 9 105 4T1-Luc cells were incubated for
30 min with a FITC-conjugated anti-CD49f antibody (BD
Pharmingen) and analyzed using a BD FACSAria flow
cytometer (BD Biosciences, Oxford, UK). The collected
data were analyzed using the FACSDiva software, version
6 (BD Biosciences). Each experimental point was assessed
in duplicate. For each experimental point, the means of
percent CD49f? cell population ±SE were calculated.
Two independent sets of experiments were performed.
Caspase-3 activity assay
The 4T1-Luc cells were treated with PBS-PEG (control)
or dipyridamole (10, 50, 100 lM) for 24 h. The medium
supplemented with PBS-PEG or dipyridamole was
replaced twice daily. After the treatment, the cells were
lysed in RIPA buffer (50 mM Tris–HCl, pH 8.0, 150 mM
NaCl, 1 % Triton X-100, 10 % glycerol) in the presence of
protease (Roche) and phosphatase (1 mM NaVO3, 50 mM
NaF) inhibitors. Then, 100 lg total protein extract was
assessed in a reaction mix containing 20 mM PIPES, pH
7.2, 100 mM NaCl, 10 mM DTT, 1 mM EDTA, 0.1 %
(w/v) CHAPS, 10 % (w/v) sucrose, and 40 lM Ac-DEVD-
AFC, the caspase-3 fluorogenic substrate (BD Pharmin-
gen). Each experimental point was assessed in triplicate.
The reaction mixes were incubated for 1 h at 37 C.
Absorbance was measured at 490 nm using a microtiter
plate reader (VICTOR3 1420 Multilabel Counter, Perkin
Elmer). For each experimental point, the mean absor-
bances ±SE were calculated. A total of two independent
sets of experiments were performed.
Clin Exp Metastasis
123
Cell migration assays
The effects of dipyridamole on cell migration were
analyzed by using chamber inserts (24-well format, poly-
carbonate membrane filter, 8 lm pore size; Corning). Here,
2.5 9 104 4T1-Luc cells or 1 9 105 MDA-MB-231T cells
were seeded into the upper chamber in DMEM without
fetal bovine serum, in the presence of PBS-PEG (control)
or dipyridamole (10, 50, 100 lM). The DMEM in the
lower chamber contained fetal bovine serum (5 % for 4T1-
Luc cells, 10 % for MDA-MB-231T cells), which served as
the chemoattractant; this was also supplemented with PBS-
PEG or dipyridamole (10, 50, 100 lM). After a 4 h incu-
bation at 37 C, the cells migrating to the lower membrane
surface were fixed and stained with hematoxylin/eosin. The
4T1-Luc cells were counted per membrane under a light
microscope. The MDA-MB-231T cells were photographed
and counted in three random fields per membrane at
109 magnification under a light microscope. Each exper-
imental point was in duplicate, and two independent sets of
experiments were carried out. For each experimental point,
the mean ± SE of the number of migrated cells per
membrane/field were calculated.
xCelligence system
The Real-Time Cell Analysis (RTCA) Instrument devel-
oped by Roche uses an xCelligence system that is based on
the Real-Time Cell Electronic Sensor (RT-CES) system,
which allows label-free dynamic monitoring of cell pro-
liferation and viability in real-time [28]. The electronic
readout of impedence is expressed as arbitrary units and
called the cell index (CI) [28]. The cell culture conditions
on the sensor device were the same as those described
above. Proliferation assays in real-time were performed as
previously described [28]. Here, 8 9 103 4T1-Luc cells/
well or 2 9 104 MDA-MB-231T cells/well were plated
into each sensor well of an E-plate 16 (ACEA Biosciences,
Inc). Four replicates for each experimental point were used.
After the DMSO (control) or dipyridamole addition, the CI
was automatically and continuously monitored every 5 min
for up to 54 h. For each experimental point, the
mean ± standard deviation (SD) of CI were calculated.
A total of two independent sets of experiments were
performed.
Immunoblotting
Total protein extracts from cells and tumor tissues were
prepared and used for immunoblotting, as previously
described [29], using the following antibodies: rabbit
anti-phospho-p44/42 MAPK (ERK1/2) (Thr 202/Tyr 204)
(1:500; Cell Signaling Technology), rabbit anti-ERK1/2
(1:500; Santa Cruz Biotechnology), rabbit anti-phospho-
IkB-a (Ser 32/36) (1:200; Santa Cruz Biotechnology),
rabbit anti-IkBa (1:3000; Abcam), rabbit anti-phospho-NF-
kB p65 (Ser 311) (1:200; Santa Cruz Biotechnology),
rabbit anti-NF-kB p65 (1:3000; Abcam), mouse anti-AKT1
(1:500; Cell Signaling Technology), rabbit anti-phospho-
AKT (Ser 473) (1:500; Cell Signaling Technology), mouse
anti-GSK-3b (1:500; BD Biosciences), rabbit anti-phos-
pho-GSK-3b (Ser 9) (1:500; Cell Signaling Technology),
mouse anti-activated b-catenin (1:500; Millipore), mouse
anti-b-catenin (1:500; BD Transduction Laboratories),
rabbit anti-cyclin D1 (1:250; Cell Signaling Technology),
rabbit anti-Survivin (1:500; Abcam) and mouse anti-c-Myc
(1:500; Santa Cruz Biotechnology). These antibodies were
detected using horseradish peroxidase–conjugated anti-
mouse (1:5000; Amersham) and anti-rabbit (1:3000;
Amersham) antibodies. A mouse anti-b-actin antibody
(1:5000; Sigma-Aldrich) was used as a control for equal
loading. Semiquantitative analyses of proteins expression
were performed. The bands were quantified by densitom-
etry to obtain an integral optical density (OD) value, which
then was normalized with respect to the b-actin value.
Then the phospho-protein/protein ratios were determined.
For each experimental point, the means of phospho-
protein/protein ratios ±SE were calculated.
Luciferase reporter assay
The HEK293T cells were seeded into 96-well plates at a
density of 1.35 9 104 cells/well and grown for 24 h. To
assess the dipyridamole induced-impairment of b-catenin
transcription activity, the cells were then transfected using
CaCl2 and 2 9 HBS reagent (50 mM HEPES, 280 mM
NaCl, 1.5 mM Na2HPO4, pH 7) with 15 ng Tk-Renilla
luciferase plasmid, 65 ng b-catenin-cmyc-pCAN plasmid,
or its empty vector as control, and 25 ng of a firefly
luciferase reporter construct, as either: TOP-FLASH, con-
taining four Tcf consensus binding sites upstream of firefly
luciferase cDNA; or FOP-FLASH, a plamid with mutated
Tcf binding sites; or their empty vector (pGL3) as control
(gift from Thomas Clevers) [30] (Upstate Biotechnology).
To assess the dipyridamole induced-impairment of NF-kB
p65 transcription activity, the cells were then transfected
using CaCl2 and 2 9 HBS reagent with 15 ng Tk-Renilla
luciferase plasmid, 65 ng p65 plasmid, or its empty vector
(pcDNA3.1) as control, and 25 ng of a firefly luciferase
reporter construct containing the immunoglobulin promoter
(IgLuc), or its empty vector (pGL3) as control. After 24 h,
the cells were incubated overnight with PBS-PEG (control)
or dipyridamole (10, 100 lM) at 37 C. After this incu-
bation, the total cell lysates were extracted using reporter
lysis buffer (Promega), and the luciferase activities were
determined using the Dual-Glo Luciferase Assay System
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(Promega) with a microplate Luminometer (Perkin Elmer,
EnVision 2102 Multilabel Reader). Firefly luciferase
activity was normalized for transfection efficiency by
Renilla luciferase activity. Each experimental point was
assessed in triplicate. For each experimental point,
the means of normalized luciferase activity ±SE were
calculated. Two independent sets of experiments were
performed.
Quantitative real-time polymerase chain reaction (qRT-
PCR)
Total RNA was isolated from cells using Trizol reagent
(Invitrogen) according to the manufacturer protocol. After
measurement of RNA yield and quality using a NanoDrop
machine (Celbio), the cDNA was synthesized by random
hexamers with iScript cDNA synthesis kits (Bio-Rad),
according to the protocols supplied by Bio-Rad. After
digestion with DNAse RNAse-free, two micrograms of total
RNA in 20 ll was used in each reaction. qRT-PCR was
performed using the SYBR Green PCR Master Mix (Applied
Biosystems) and the Applied Biosystems Model 7900HT
sequence detection system, according to the protocols sup-
plied by Applied Biosystems. The primers were designed
with the Primer Express 2.1 program (Applied Biosystems).
All qRT-PCRs were performed in duplicate, with 70 ng ss-
cDNA used in each 10-ll reaction. b-actin mRNA was
used to normalize the mRNA concentrations. The primer
sequences for the tested genes were the following:
m-p27 forward, 50-CTTCCGCCTGCAGAAATCTC-30;
m-p27 reverse, 50-CCATATCCCGGCAGTGCTT-30;
m-matrix metalloproteinase 9 (MMP9) forward, 50-TA
CCCGCTGTATAGCTACCTCGA-30;
m-MMP9 reverse, GCCACGACCATACAGATACT
GGA;
m-phosphoglucokinase (PGK) forward, 50-GCATCA
AATTCTGCTTGGACAATGGA-30;
m-phosphoglucokinase (PGK) reverse, 50-CTCTACAT
GAAAGCGGAGGTTTTCC-30;
m-b-actin forward, 50-AGGCCAACCGTGAAAAGA
TG-30;
m-b-actin reverse, 50-GCCTGGATGGCTACGTACA
TG-30;
h-p27 forward, 50- CTGCAGGAACCTCTTCGGC-30;
h-p27 reverse, 50- GCTCGCCTCTTCCATGTCTCT-30;
h-b-actin forward, 50-GACCCAGATCATGTTTGAGA
CCTT;
h-b-actin reverse, 50-CCAGAGGCGTACAGGGATAG
C-30.
For statistical analysis of the gene expression data, the
mean fold change = 2-(average DDCt) ± SEM was calcu-
lated using the mean difference in the DCt between the
genes and the internal control. The DCt was calculated
using the differences in the mean Ct between the genes and
the internal control.
In vivo mouse experiments
Athymic nude and Balb/c mice were purchased from
Harlan. All of the animal experiments were conducted
according to Italian law and under a National Cancer
Institute approved Animal Use Agreement. Every effort
was made to minimize the suffering of the animals, and to
minimize the number of animals used. Seven-week-old
mice were anesthetized with 3 % avertin (Sigma) solution,
and then had 4T1-Luc cells either implanted into the VIII
right-side mammary gland or injected into the left ventricle
of the heart. The MDA-MB-231T cells were injected into
the tail vein of 7-week-old athymic nude mice. The 4T1-
Luc xenograft mice were treated with vehicle (PBS-PEG)
or dipyridamole (15, 30, 60 mg/kg/day), for 5 days/week
(2 injections/day) for 2–4 weeks, beginning one or two
weeks after implantation/injection. The MDA-MB-231T
xenograft mice were treated with vehicle (PBS-PEG) or
30 mg/kg/day dipyridamole (2 injections/day) for 6 days/
week for 6 weeks, beginning one day after injection. The
treatments were administered intraperitoneally or by oral
gavage. At the end of the experiments, the primary tumors
and the metastatic lungs were dissected out and embedded
in paraffin, for immunohistochemistry (IHC) analyses.
In vivo bioluminescence imaging
Cell implantation and tumor growth were monitored by
bioluminescence imaging (BLI) acquisition using an IVIS
3D Illumina Imaging System (Xenogen/Caliper). Briefly,
the mice were anesthetized with isoflurane, injected intra-
peritoneally with D-luciferin solution (15 mg/ml stock;
100 ll per 10 g body weight), and imaged. For the intra-
cardiac-injected mice, two acquisitions (ventral and dorsal)
were made per mouse; while for the mammary fat-pad
implanted mice, one acquisition (ventral) was made per
mouse. To quantify the bioluminescence, the integrated
fluxes of photons (photons per s) within each area of
interest were determined using the Living Images Software
Package 3.2 (Xenogen-Caliper). For each intracardiac-
injected mouse, the ventral and dorsal integrated fluxes of
photons were added together. According to the time and
treatment, the mean ± SE of the photon integrated fluxes
were calculated for each experimental point.
Lung metastases detection
The MDA-MB-231T breast cancer xenograft mice were
sacrificed on day 45 of PBS-PEG or dipyridamole
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treatment, and their lungs were removed and infused with
Bouin’s solution. After fixing in Bouin’s solution for 48 h,
the number of macroscopically visible metastases on the
lung surface was quantified. The tissues were embedded in
paraffin for IHC analysis.
Immunohistochemistry
Paraffin sections (7 lm thick) of the tumor specimens were
incubated overnight at 4 C with the following antibodies:
rabbit anti-Ki67 (1:100; Abcam), rabbit anti-cleaved cas-
pase-3 (1:500; Cell Signaling Technology), mouse anti-
activated b-catenin (1:50; Millipore), rabbit anti-IkBa
(1:25; Abcam), rabbit anti-phospho-NF-kB p65 (Ser 311)
(1:100; Santa Cruz Biotechnology), rabbit phospho-p44/42
MAPK (ERK1/2) (Thr202/Tyr204) (1:100; Cell Signaling
Technology), rat anti-mouse Ly-6G and Ly-6C Gr1 (1:250;
BD Pharmingen), rabbit anti-CD11b (1:3000; Abcam),
rabbit anti-CD163 (1:500; Santa Cruz Biotechnology), rat
anti-CD68 (1:200; Abcam), and rabbit anti-S100A4 (gift
from Eugene Lukanidin). The negative controls omitted the
primary antibody. Detection was achieved with the Liquid
DAB ? Substrate Chromogen System (Dako). All of the
slides were counterstained with Gill’s hematoxylin (Bio-
Optica). For statistical analysis, both positive nuclei/cells
and total cells were counted in three random fields per
section under 409 magnification, and the percentages of
positive cells in each field were calculated from the sec-
tions obtained from at least three different mice. Then the
average of %positive nuclei/cells in each field per section
was calculated and the statistical analysis was performed.
ELISA assays
Blood samples were collected from vehicle- and dipyrid-
amole-treated mice after the mammary fat-pad implanta-
tion and allowed to clot. The sera were separated by
centrifugation at 3,0009g for 30 min, and immediately
frozen and stored at -80 C until use. Interleukin-1a (IL-
1a), interleukin-1b (IL-1b), granulocyte colony stimulating
factor (G-CSF), granulocyte–macrophage colony stimu-
lating factor (GM-CSF), monocyte chemotactic protein 1
(MCP-1), macrophage inflammatory protein 1a (MIP-1a),
stem cell factor (SCF), and Rantes cytokines levels were
analyzed in the sera collected, using the Mouse Inflam-
mation ELISA Strip for Profiling 8 Cytokines (Signosis
BioSignal Capture), according to the manufacturer
protocol.
Statistical analysis
The statistical comparisons of the data from the in vitro and
in vivo treatments were performed using Students’ t test
and ANOVA, respectively. Statistical significance was
established at p B 0.05.
Results
Dipyridamole impairs in vitro cell growth
To assess the dipyridamole ability to impair cell growth, in
vitro cell proliferation assays were performed on triple-
negative murine 4T1-Luc and human MDA-MB-231T
breast-cancer cells. Dipyridamole decreased the prolifera-
tion of both the 4T1-Luc and the MDA-MB-231T cells, in
dose- and time-dependent manners, as compared to the
PBS-PEG–treated (control) cells (Fig. 1a). Dipyridamole
significantly reduced the proliferation of both of these cell
lines at almost all of the experimental points tested
(Fig. 1a; 4T1-Luc, p \ 0.001; MDA-MB-231T p \ 0.035;
Students’ t test). The exception here was 24 h treatment of
4T1-Luc cells with 10 lM dipyridamole, as compared to
these PBS-PEG–treated cells (p = 0.2, Students’ t test).
Similar results were obtained in real-time proliferation
assays using the xCelligence System. Dipyridamole-treated
4T1-Luc cells did not show any significant changes in their
CI during the first hours after dipyridamole addition; this
was followed by a significant reduced increase in CI, as
compared to the vehicle (DMSO) control (Fig. 1b, left
panel). With the MDA-MB-231T cells, dipyridamole
caused a transient decrease in CI during the first hours after
its addition, which was then followed by a significant
reduced increase in CI of these dipyridamole treated cells,
as compared to the vehicle (DMSO)-treated cells (Fig. 1b,
right panel).
Fig. 1 In vitro effects of dipyridamole. a Representative cell
proliferation assay (of two experiments performed with similar
results) with 4T1-Luc and MDA-MB-231T cells treated with PBS-
PEG (control) or dipyriramole (as indicated). Data are mean ± SE.
*p \ 0.001, **p \ 0.035 (Students’ t test). b Representative dynamic
monitoring of cell proliferation (each with two experiments per-
formed with similar results) of 4T1-Luc (left panel) and MDA-MB-
231T (right panel) cells treated with DMSO (control) or 50 lM
dipyridamole (as indicated). Arrows, time of vehicle/dipyridamole
addition, to which cell index (CI) values were normalized. Data are
mean ± SD. c Representative FACS analysis for cell-cycle phases (of
two experiments performed with similar results) of 4T1-Luc and
MDA-MB-231T cells treated for 24 h with PBS-PEG or dipyridamole
(as indicated). Data are mean ± SE. *p \ 0.01 (Students’ t test).
d Immunoblotting for cyclin D1 in 4T1-Luc and MDA-MB-231T
cells treated for 24 h with PBS-PEG or dipyridamole (as indicated).
b-actin used as control for equal loading. e p27 gene expression in
4T1-Luc and MDA-MB-231T cells treated for 24 h with PBS-PEG or
dipyridamole (as indicated). Data are mean ± SEM. f Representative
FACS analysis for apoptosis evaluation (of two experiments
performed, with similar results) of 4T1-Luc and MDA-MB-231T
cells treated for 24 h with PBS or dipyridamole (as indicated). Data
are mean ± SE
c
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To unravel the molecular mechanisms involved in this
dipyridamole-induced reduction of cell proliferation, we
analyzed cell-cycle perturbation by dipyridamole. Signifi-
cant effects were seen on the cell cycle at 50 lM dipy-
ridamole only for the MDA-MB-231T cells, which resulted
in a 19.3 % increase in the G1-phase cell population,
as compared to the PBS-PEG–treated cells (Fig. 1c;
p = 0.0013, Students’ t test). To further address dipyrid-
amole-induced impairment of cell proliferation, the levels
of cyclin D1 protein (which promotes progression through
the G1-S phase of the cell cycle) and p27 mRNA (a cyclin-
dependent kinase inhibitor that blocks the cell cycle in the
G0/G1 phase) were measured by Western blotting and qRT-
PCR respectively. Dipyridamole determined a significant
depletion of cyclin D1 protein both in 4T1-Luc and MDA-
MB-231T cells as compared to the PBS-PEG–treated
(control) cells (Fig. 1d). Similarly, a significant increased
expression of p27 mRNA was observed in both dipyrid-
amole-treated 4T1-Luc and MDA-MB-231T cells as
compared to the PBS-PEG–treated (control) cells (Fig. 1e;
4T1-Luc, 10 lM dipyridamole p = 0.044, 100 lM
dipyridamole p = 0.022; MDA-MB-231T, 100 lM dipyrid-
amole p = 0.039; Students’ t test).
We also analyzed the perturbation in apoptosis caused
by this dipyridamole treatment, using an Annexin V assay.
As shown in Fig. 1f, although the dipyridamole determined
a decrease in percent population of alive cells and a cor-
responding increase in percent population of apoptotic cells
as compared to PBS-PEG–treated cells, these changes did
not reach statistical significance. Then a caspase-3 activity
assay with the 4T1-Luc cells showed a small, but signifi-
cant, effect on apoptosis at 50 and 100 lM dipyridamole
(Fig. S1; p = 0.03 for both, Students’ t test). These data
thus support the concept that the impairment of cell pro-
liferation observed in the 4T1-Luc and MDA-MB-231T
cells is related to an arrest in the G1 phase of the cell cycle,
thus further strengthening the results already presented by
Goda and collaborators [15].
In summary, dipyridamole inhibited cell proliferation in
both these two triple-negative breast-cancer cell lines.
Dipyridamole impairs in vitro cell motility
To determine dipyridamole effects on cell migration, in
vitro cell motility assays were performed with these 4T1-
Luc and MDA-MB-231T breast-cancer cells. Here, 50 and
100 lM dipyridamole significantly impaired 4T1-Luc cell
migration in a dose-dependent manner (Fig. 2a; p = 0.039,
0.018, respectively, Students’ t test). Similarly, 100 lM
dipyridamole treatment almost completely blocked MDA-
MB-231T cell motility (Fig. 2b; p \ 0.0001, Students’
t test).
In summary here, dipyridamole inhibited cell motility in
both these two breast-cancer cell lines.
Dipyridamole impairs in vivo primary tumor growth
Dipyridamole was further investigated in an in vivo 4T1-
Luc breast-cancer xenograft mouse model. To determine
the effects of dipyridamole on primary tumor growth, the
4T1-Luc cells were orthotopically implanted into the
mammary fat pads of Balb/c syngeneic mice. In the first set
of experiments, 5 9 104 4T1-Luc cells were implanted.
Vehicle (PBS-PEG control) or dipyridamole (15 or 30 mg/
kg/day for 5 days/week) were administered intraperitone-
ally beginning on day 7 post-implantation. Both of these
dipyridamole treatments showed significant reductions in
the primary tumor volume compared to the PBS-PEG
control mice (Fig. S2). At the 15 mg/kg/day dose, dipy-
ridamole inhibited the mean tumor size on day 21 post-
implantation by 67.5 %, as compared to the control (Fig.
S2A; p = 0.0433, ANOVA). At the higher, 30 mg/kg/day,
dipyridamole dose, there was essentially no tumor growth
in the dipyridamole-treated animals (Fig. S2B; p = 0.0182,
ANOVA).
Fig. 2 Dipyridamole impairs
cell motility. Representative
motility assays (each with two
experiments performed with
similar results) in 4T1-Luc
(a) and MDA-MB-231T
(b) cells treated for 4 h with
PBS-PEG or dypiridamole
(as indicated). Data are
mean ± SE. a *p = 0.039,
**p = 0.018. b *p \ 0.0001
(Students’ t test)
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To confirm these data, the number of cells implanted
into the mammary fat pad of these Balb/c syngeneic mice
was increased (by fivefold, to 2.5 9 105 4T1-Luc cells)
and the beginning of the vehicle and dipyridamole treat-
ments was delayed to day 14 post-implantation. At this
stage, the mean tumor size according to the BLI mea-
surements was at least one order of magnitude greater than
the primary tumors treated in the initial experiments. At the
same time, the intraperitoneal dipyridamole treatment was
increased to 60 mg/kg/day (5 days/week). Figure 3a (on
the left) shows representative images of these PBS-PEG
control and dipyridamole-treated mice following the
4T1-Luc cell implantation (day 0) and at 42 days post-
implantation. Overall, the mice treated with dipyridamole
showed a significant 76.7 % reduction in tumor volume on
day 42 post-implantation, as compared to the controls
(Fig. 3a on the right; p = 0.0429, ANOVA).
To further demonstrate the dipyridamole impairment of
primary tumor growth, the levels of Ki67, a marker of
tumor-cell proliferation, were assessed by IHC on sections
from the tumors of vehicle- and dipyridamole-treated mice.
Representative images of Ki67 staining are shown in
Fig. 3b, while the quantification shown in Fig. 3c illus-
trates that overall, the percentage of Ki67-positive tumor
cells nuclei was significantly reduced by 19.7 % in tumors
from those dipyridamole treated mice, as compared to
those from the control mice (p = 0.0032, ANOVA). The
cleaved caspase-3 levels, a marker of apoptosis, were also
determined by IHC on tumor sections from these vehicle-
and dipyridamole-treated mice. However, no significant
differences were seen between the percentages of cleaved-
caspase-3-positive tumor cells of tumors from these vehi-
cle- and dipyridamole-treated mice (Fig. S3A; p = 0.0962,
ANOVA).
In summary, intraperitoneally delivered dipyridamole
inhibited in vivo 4T1-Luc primary tumor growth over a
range of inocula.
Dipyridamole impairs in vivo metastases
To determine the effects of dipyridamole on metastasis foci
formation and growth, experimental metastasis assays were
conducted using both the 4T1-Luc and MDA-MB-231T
cells. The 4T1-Luc cells were injected into the arterial
circulation via the left cardiac ventricle of Balb/c synge-
neic mice. The vehicle (PBS-PEG control) and the
dipyridamole (30 mg/kg/day for 5 days/week) were
administered intraperitoneally beginning on day 7 post-
injection, at which time a few metastatic foci were detected
by BLI (data not shown). In Fig. 3d (on the left) the rep-
resentative images of mice on the day of injection (day 0)
and at week 3 post-injection (2 weeks of treatment) show
widespread metastatic involvement in the control mice, and
visibly fewer and smaller metastatic foci in the dipyrid-
amole-treated mice. The overall BLI data analysis shows
that the total flux per mouse was decreased by 50.3 % in
the dipyridamole treated mice, as compared to the vehicle-
treated mice (Fig. 3d on the right; p = 0.0292, ANOVA).
In the parallel MDA-MB-231T model, 1 9 106 MDA-
MB-231T cells were injected into the tail vein of nude
mice, and lung metastasis formation was analyzed. The
vehicle (PBS-PEG control) and the dipyridamole (30 mg/
kg/day for 6 days/week) were administered either intra-
peritoneally or by oral gavage, to also determine the clin-
ical efficacy in a comparison of these delivery modes in
vivo. Administration started on day 1 post-injection.
Figure 3e (on the left) shows representative images of the
mouse lungs from day 45 post-injection. The count of the
surface pulmonary metastases showed that dipyridamole
did not inhibit metastasis formation when it was adminis-
tered by oral gavage, while intraperitoneal delivery of
dipyridamole resulted in a significant overall 47.5 %
reduction in these mean pulmonary metastases, as com-
pared to the lungs of the control mice (Fig. 3e on the right;
p = 0.0122, ANOVA).
The Ki67 and cleaved caspase-3 levels were also
determined by IHC on sections of the lung metastases from
these intraperitoneally vehicle- and dipyridamole-treated
mice. There were no significant differences in the per-
centages of Ki67-positive tumor cells nuclei or cleaved-
caspase-3-positive tumor cells between these lung metas-
tases from the control and the dipyridamole-treated mice
(Fig. S3B and C respectively; p = 0.5355, p = 0.1888
respectively, ANOVA).
In summary, intraperitoneal delivery of dipyridamole
inhibited metastasis formation in two model systems of
triple-negative breast cancer. In particular, the dipyridam-
ole-induced inhibition of metastasis formation in this
MDA-MB-231T breast-cancer mouse xenograft model
suggests that dipyridamole can be considered as a metas-
tasis-preventing agent, as it was administered a day after
the tumor-cell injection, when the circulating tumor cells
were not yet established in the lung. On the other hand, the
therapeutic efficacy of dipyridamole in metastasis treat-
ment is suggested by its efficacy to inhibit metastasis for-
mation in this 4T1-Luc breast-cancer mouse xenograft
model, in which the treatment was delayed to day 7 after
tumor-cell injection, when a few metastatic foci could
already be detected.
In all of these mouse experiments, there were neither
behavioral changes nor weight loss due to potential drug
toxicity in these dipyridamole-treated mice, as compared to
the control mice. This is also illustrated by the weights of
the athymic nude mice that were injected with MDA-MB-
231T cells, as given in Figure S4, where there were no
signs of drug toxicity.
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Dipyridamole inhibits key signaling pathways
The strong cytostatic effects of dipyridamole suggested
that it can affect key signaling pathways in tumors. To
identify these signaling pathways that are affected by
dipyridamole, we analyzed dipyridamole-induced pertur-
bations of activation of the AKT, ERK1/2-MAPK and Wnt
signaling pathways in these 4T1-Luc cells. The expression
levels of AKT and Ser 473 phosphorylated AKT proteins
(P-AKT) were determined by western blotting analyses
(Fig. 4a). As shown in Fig. 4b, no change in P-AKT/AKT
ratio was observed in 4T1-Luc cells after in vitro dipy-
ridamole treatment, which overall thus indicates that
dipyridamole does not alter the activation of this signaling
pathway. To analyze the dipyridamole-induced perturba-
tion of ERK1/2-MAPK signaling pathway, we assessed by
western blotting the expression levels and the phosphory-
lation states of ERK1/2 proteins, the major effectors of
this signaling pathway (Fig. 4a). Significant reductions
of phospho-ERK1/ERK1 (P-ERK1/ERK1) and phospho-
ERK2/ERK2 (P-ERK2/ERK2) ratios were observed in
4T1-Luc cells after in vitro 100 lM dipyridamole treat-
ment as compared to PBS-PEG–treated cells, thus resulting
in an impairment of ERK1/2-MAPK pathway activation
(Fig. 4b; P-ERK1/ERK1 p = 0.017; P-ERK2/ERK2
p = 0.047; Students’ t test). Similarly to address the effect
of dipyridamole on Wnt signaling pathway, the protein
levels of b-catenin (a major effector of the canonical
Wnt pathway), of GSK-3b (which in turn phosphorylates
b-catenin thus causing its degradation and consequently
the inhibition of Wnt pathway), and Ser 9 phosphorylated
GSK-3b (P-GSK-3b; the GSK-3b inactivated form) were
determined by western blotting analyses in 4T1-Luc cells
after in vitro dipyridamole treatment (Fig. 4a). As shown in
Fig. 4b, dipyridamole decreased the P-GSK-3b/GSK-3b
ratio, thus determining in an increased activation of GSK-
3b kinase activity, then resulting in an impairment of Wnt
signaling. According to this data, the activated b-catenin
levels were found reduced (Fig. 4a), which thus indicated
dipyridamole-induced attenuation of the Wnt signaling
pathway.
To further confirm these results, we transiently transfected
HEK293T cells with the TOP/FOP-FLASH system [30],
which allows the detection of b-catenin transcriptional acti-
vation by measuring luciferase reporter activity. After trans-
fection, these cells were treated with PBS-PEG (as control
vehicle) and dipyridamole, and their luciferase activities were
measured. As shown in Fig. 4c, in absence of the plasmid
encoding b-catenin the HEK293T cells transfected with the
empty vector (pGL3) and with each of the plasmids of the
TOP/FOP-FLASH system showed a very low level of nor-
malized firefly luciferase activity. In the presence of the
plasmid encoding b-catenin an increased level of normalized
firefly luciferase activity was observed in those cells trans-
fected with the TOP-FLASH plasmid containing four Tcf
consensus binding sites upstream of firefly luciferase cDNA.
As expected, the normalized firefly luciferase activity did not
increase in those cells transfected with FOP-FLASH plasmid
with mutated Tcf binding sites or with pGL3 vector. The
dipyridamole treatment of HEK293T cells cotransfected with
the plasmid encoding b-catenin and with the TOP-FLASH
plasmid determined a significantly reduced increase of the
normalized firefly luciferase activity as compared to the
control cells (Fig. 4c; p = 0.006, Students’ t test).
We then investigated this dipyridamole-induced Wnt
pathway attenuation in terms of the expression of the
CD49f, cyclin D1, survivin and c-Myc proteins, which are
all early targets of the Wnt pathway [31]. Here, dipyrid-
amole significantly decreased the percentage of 4T1-Luc
breast-cancer cells that expressed the membrane antigen
CD49f (Fig. 4d; p = 0.008, Students’ t test), and as pre-
viously showed in Fig. 1d, significantly decreased the
expression of cyclin D1. In parallel, in the MDA-MB-231T
cells, dipyridamole significantly decreased the expression
levels of all proteins including cyclin D1 (Fig. 1d), survi-
vin and c-Myc (Fig. 4e).
Previous reports have shown that dipyridamole attenuates
the activation of the NF-kB signaling pathway [32, 33].
Therefore, we investigated whether this was also the case in
the 4T1-Luc breast-cancer cells, by determination of the
expression levels of IkBa, an inhibitor of the NF-kB signaling
pathway. Here, 4 h of in vitro dipyridamole treatment of the
4T1-Luc cells at both 10 and 100 lM did not alter the IkBa
Fig. 3 Dipyridamole impairs primary tumor growth and metastasis in
vivo. a On the left: representative bioluminescent images of mice
implanted with 4T1-Luc cells in the mammary fat pad at day 0 and
42 days after intraperitoneally administered treatments with vehicle
and 60 mg/kg/day dipyridamole (i.e. 4 weeks treatment). On the
right: time-course of bioluminescent signals from 4T1-Luc tumor
cells implanted into mouse mammary fat pad at day 0, followed by
intraperitoneally administered treatments with vehicle and 60 mg/kg/
day dipyridamole on day 14. Data are total flux mean ± SE.
*p = 0.0429 (ANOVA). b Representative images of Ki67 IHC in
sections of 4T1-Luc primary tumors from a. c Percentages of Ki67
positive tumor cells nuclei in sections of 4T1-Luc primary tumors
from a. Data are mean ± SEM. p = 0.0032 (ANOVA). d On the left:
representative bioluminescent images of mice intracardiacally
injected with 4T1-Luc cells at day 0 and at week 3, after week 1
treatments with vehicle and 30 mg/kg/day dipyridamole intraperito-
neally administered (i.e. 2 weeks treatment). Ventral and dorsal
photographs were taken for each mouse. On the right: representative
time-course of bioluminescent signals (of two experiments performed
with similar results) from mice injected intracardiacally with 4T1-Luc
tumor cells. Data are total flux mean ± SE. *p = 0.0292, ANOVA.
e On the left: representative images of lungs from athymic nude mice
injected with MDA-MB-231T cells via the tail vein and treated with
vehicle or 30 mg/kg/day dipyridamole, delivery either by oral gavage
or intraperitoneally (IP; as indicated). On the right: lung metastasis
counts from left panel. Data are mean ± SEM. *p = 0.0122
(ANOVA)
b
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level (Fig. S5A). However, 24 h of treatment with 10 and
100 lM dipyridamole resulted in the up-regulation of IkBa
(Fig. 5a), thus indicating dipyridamole-induced attenuation
of the NF-kB signaling pathway. To further address this point,
the expression levels of phosphorylated IkBa (P-IkBa), p65
and phosphorylated p65 (P-p65) proteins were determined by
western blotting analyses (Fig. 5a). As shown in Fig. 5b, a
reduction of both the P-IkBa/IkBa and P-p65/p65 ratios that
reached the limit of significance was observed at 100 lM
dipyridamole (p = 0.06, p = 0.077 respectively, Students’
t test), which thus further suggests dipyridamole-induced
attenuation of NF-kB signaling pathway. We then transiently
cotransfected HEK293T cells with a plasmid encoding p65
and a plasmid containing the immunoglobulin promoter,
which is responsive to p65, upstream of firefly luciferase
cDNA (IgLuc vector). After transfection, these cells were
treated with PBS-PEG (control-vehicle) and dipyridamole,
and their luciferase activities were measured. As shown in
Fig. 5c, in absence of the plasmid encoding p65 the
HEK293T cells transfected with the empty vector (pGL3) and
Fig. 4 Dipyridamole impairs Wnt and ERK1/2-MAPK signaling
pathways in vitro. a Immunoblotting for phospho-AKT, AKT,
phospho-ERK1/2, ERK1/2, phospho-GSK-3b, GSK-3b, total and
activated b-catenin in 4T1-Luc cells treated for 4 h with PBS-PEG or
dipyridamole (as indicated). b-actin used as control for equal loading.
b The densitometer analyses for the proteins from a. Data are
mean ± SE. *P-ERK1/ERK1 p = 0.017; P-ERK2/ERK2 p = 0.047
(Students’ t test). c Representative luciferase activity in TOP/FOP
FLASH system transfected HEK293T cells (of two experiments
performed with similar results) after overnight treatment with PBS-
PEG or dipyridamole (as indicated). Data are mean ± SE.
*p = 0.006 (Students’ t test). d Representative analysis for percent-
age positivity to CD49f, a known target of Wnt pathway, (of two
experiments performed with similar results) of 4T1-Luc cells treated
for 24 h with PBS-PEG or dipyridamole (as indicated). Data are
mean ± SE. *p = 0.008 (Students’ t test). e Immunoblotting for
c-Myc and survivin in MDA-MB-231T cells treated for 24 h with
PBS-PEG or dipyridamole (as indicated). b-actin used as control for
equal loading
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with IgLuc plasmid showed a low level of normalized firefly
luciferase activity. In the presence of the plasmid encoding
p65 an increased level of normalized firefly luciferase activity
was observed in only those cells transfected with the IgLuc
plasmid. As expected, the normalized firefly luciferase
activity did not increase in those cells transfected with pGL3
vector, thus further confirming the specificity of responsive-
ness of immunoglobulin promoter within our in vitro assay.
At this time, we found the dipyridamole treatment of
HEK293T cells cotransfected with the plasmid encoding p65
and with Ig-Luc plasmid induced less of an increase in the
normalized firefly luciferase activity as compared to the
control transfected cells (Fig. 5c; 10 lM dipyrid-
amole p = 0.04; 100 lM dipyridamole p = 0.003; Students’
t test).
We then investigated this NF-kB pathway attenuation in
terms of the expression of its main targets. We already
showed the down-regulation of cyclin D1 (Fig. 1d), c-Myc
and survivin (Fig. 4e), which are known to be early targets
of both Wnt and NF-kB signaling pathways [34, 35]. To
further validate this, we analyzed the expression of the
MMP9 mRNA, another target of NF-kB [34], in 4T1-Luc
cellular model. Here we found that 100 lM dipyridamole
significantly decreased the MMP9 gene expression (Fig. 5d;
p = 0.039, Students’ t test).
In conclusion to exclude any unspecific target regula-
tion, we verified the expression of phosphoglucokinase
gene (PGK), which is known to be not a target of all those
above mentioned signaling pathways (ERK1/2-MAPK,
Wnt and NF-kB). PGK mRNA expression was analyzed by
qRT-PCR. As shown in Figure S5B, dipyridamole did not
alter the PGK gene expression. Although it is not still
possible to specifically define at this time how mechanis-
tically dipyridamole targets ERK1/2-MAPK, NF-kB and
Wnt signaling pathways, the results here presented are
showing no effect on AKT signaling pathway and on PGK
gene expression, thus demonstrating some level of speci-
ficity of dipyridamole on those above mentioned pathways.
Future studies will need to address how dipyridamole infer
mechanistically those pathways.
We also investigated the in vivo ability of dipyridamole
to impair the Wnt, ERK1/2-MAPK and NF-kB signaling
pathways. Here, the percentages of tumor cells nuclei
positive for activated b-catenin, phospho-p65 and phospho-
ERK1/2 and the percentages of tumor cells positive for
IkBa were also evaluated on tumor sections by IHC.
Fig. 5 Dipyridamole impairs
NF-kB signaling pathway in
vitro. a Immunoblotting for
phospho-IkBa, IkBa, phospho-
p65 and p65 in 4T1-Luc cells
treated for 24 h with PBS-PEG
or dipyridamole (as indicated).
b-actin used as control for equal
loading. b The densitometry
analyses for the proteins from
a. Data are mean ± SE.
c Representative luciferase
activity in p65 and IgLuc
transfected HEK293T cells (of
two experiments performed
with similar results) after
overnight treatment with
PBS-PEG or dipyridamole (as
indicated). Data are
mean ± SE. *10 lM
dipyridamole p = 0.04;
100 lM dipyridamole
p = 0.003 (Students’ t test).
d Expression of MMP9 gene, a
known target of NF-kB
pathway, in 4T1-Luc cells
treated for 24 h with PBS-PEG
or dipyridamole (as indicated).
Data are mean ± SEM.
*p = 0.039 (Students’ t test)
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Representative images of activated b-catenin staining
are shown in Fig. 6a. In the 4T1-Luc mammary fat-pad
mouse xenograft model, the percentage of activated
b-catenin-positive tumor cells nuclei was significantly
reduced by 38.6 % in tumors from the dipyridamole-trea-
ted mice, as compared to those from the vehicle-treated
mice (Fig. 6b; p \ 0.0001, ANOVA). In the MDA-MB-
231T cell in vivo experimental metastasis model, the per-
centage of activated b-catenin–positive tumor cells nuclei
in lung metastases from mice treated intraperitoneally with
dipyridamole was significantly reduced by 16.4 %, as
compared to tumors from the control mice (Fig. 6c;
p = 0.0055, ANOVA). However, there were no significant
differences in the percentages of activated-b-catenin–
positive tumor cells nuclei in the lung metastases following
the oral gavage dipyridamole treatment in these mice, as
compared to the control mice (Fig. 6c; p = 0.8619,
ANOVA). In parallel, the expression levels of the cyclin
D1 and c-Myc proteins were also reduced in these 4T1-Luc
primary tumors from the dipyridamole-treated mice, as
compared those from the control mice (Fig. S6).
Additionally we evaluated in vivo the phospho-ERK1/2
inhibition as already encountered in vitro. Representative
images of phospho-ERK1/2 staining are shown in Fig. 6a.
In the 4T1-Luc mammary fat-pad mouse xenograft model, the
percentage of phospho-ERK1/2–positive tumor cells nuclei
was significantly reduced by 6.4 % in tumors from the dipy-
ridamole-treated mice, as compared to those from the vehicle-
treated mice (Fig. 6d; p = 0.0187, ANOVA). In the MDA-
MB-231T cell in vivo experimental metastasis model, the
percentage of phospho-ERK1/2–positive tumor cells nuclei in
lung metastases from these mice treated intraperitoneally
with dipyridamole was significantly reduced by 25.05 %,
as compared to tumors from the control mice (Fig. 6e;
p = 0.0129, ANOVA). Similarly to the results obtained for
the evaluation of activated b-catenin, there were no significant
differences in the percentages of phospho-ERK1/2–positive
tumor cells nuclei in the lung metastases following the oral
gavage dipyridamole treatment in these mice, as compared to
the control mice (Fig. 6e; p = 0.135, ANOVA).
Then we investigated in vivo the NF-kB pathway by
measuring the number of IkBa– positive tumor cells in those
treated animals. For IkBa (whose representative images are
shown in Fig. 6a), in both the 4T1-Luc mammary fat-pad
xenograft model and the MDA-MB-231T experimental
metastasis model, intraperitoneally administered dipyrid-
amole doubled the percentages of IkBa-positive tumor cells
(Fig. 6f; p = 0.0487; Fig. 6g; p = 0.0019, respectively,
ANOVA). Also, similar to that seen for activated b-catenin
and phospho-ERK1/2, there were no significant differences
in the percentages of IkBa-positive tumor cells in the lung
metastases from the mice treated with oral gavage of dipy-
ridamole, as compared to tumors from the control mice
(Fig. 6g; p = 0.0893, ANOVA). According to the results for
IkBa, in the 4T1-Luc mammary fat-pad mouse xenograft
model, the percentage of phospho-p65–positive tumor cells
nuclei (whose representative images are shown in Fig. 7a)
was significantly reduced by 67.82 % in tumors from the
dipyridamole-treated mice, as compared to those from the
vehicle-treated mice (Fig. 7b; p \ 0.0001, ANOVA). In the
MDA-MB-231T cell in vivo experimental metastasis model,
the percentage of phospho-p65–positive tumor cells nuclei
in lung metastases from these mice treated both by oral
gavage and intraperitoneally with dipyridamole was sig-
nificantly reduced by 17.67 and 24.88 % respectively, as
compared to tumors from the control mice (Fig. 7c; oral
gavage administration p = 0.0002; intraperitoneal admin-
istration p \ 0.0001; ANOVA). In this case, although both
dipyridamole treatments resulted in a significant decrease of
percentage of phospho-p65–positive tumor cells nuclei as
compared to control tumors, the intraperitoneal adminis-
tration of the drug was more effective than the oral gavage
delivery. In fact the comparison between these two treat-
ment groups showed the intraperitoneally delivered dipy-
ridamole determined a significant reduced percentage of
phospho-p65–positive tumor cells nuclei (7.21 %) as com-
pared to tumors from mice administrated by oral gavage
dipyridamole (Fig. 7c; p = 0.0048, ANOVA).
In summary, dipyridamole-induced inhibition of the
Wnt, ERK1/2-MAPK and NF-kB signaling pathways was
seen both in in vitro studies and in in vivo primary
tumorigenesis and metastasis assays.
Dipyridamole impairs the tumor microenvironment
The NF-kB pathway is critical for both the tumor cells and
the inflammatory cells in the tumor microenvironment [36].
Fig. 6 Dipyridamole impairs signaling pathways in vivo. a Repre-
sentative images of activated b-catenin, phospho-ERK1/2 and IkBa
IHC in sections of 4T1-Luc primary tumors and MDA-MB-231T lung
metastases from mice treated with intraperitoneally administered
PBS-PEG or dipyridamole (as indicated). b Percentages of activated
b-catenin positive tumor cells nuclei in sections of 4T1-Luc primary
tumors from mice treated with intraperitoneally administered vehicle
or dipyridamole (as indicated). Data are mean ± SEM. p \ 0.0001
(ANOVA). c Percentages of activated b-catenin positive tumor cells
nuclei in sections of lung metastases from athymic nude mice injected
with MDA-MB-231T cells and treated with vehicle or dipyridamole
(intraperitoneal or oral gavage administration). Data are mean ± -
SEM. Intraperitoneal administration p = 0.0055 (ANOVA). d Per-
centages of phospho-ERK1/2 positive tumor cells nuclei in sections of
4T1-Luc primary tumors as for b. Data are mean ± SEM. p = 0.0187
(ANOVA). e Percentages of phospho-ERK1/2 positive tumor cells
nuclei in sections of lung metastases as for c. Data are mean ± SEM.
Intraperitoneal administration p = 0.0129 (ANOVA). f Percentages
of IkBa positive cells in sections of 4T1-Luc primary tumors as for
b. Data are mean ± SEM. p = 0.0487 (ANOVA). g Percentages of
IkBa positive cells in sections of lung metastases as for c. Data are
mean ± SEM. Intraperitoneal administration p = 0.0019 (ANOVA)
c
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To determine the effects of dipyridamole treatment on
immune-cell infiltration into the tumor microenvironment,
IHC analyses of tumor-associated macrophages (TAMs)
and myeloid-derived suppressor cells (MDSCs) were con-
ducted on sections of primary tumors from the breast
cancer xenograft mice implanted with 4T1-Luc cells into
the mammary fat-pad that had been intraperitoneally trea-
ted with vehicle (PBS-PEG) or 60 mg/kg/day (5 days per
week) dipyridamole. Representative images of this staining
are shown in Fig. 8a. For both the MDSCs (CD11b? and
Gr1? cells) (Fig. 8b, c) and TAMs (CD163? and CD68?
cells) (Fig. 8d, e), infiltration into the tumor microenvi-
ronment was significantly decreased by dipyridamole
treatment, as compared to vehicle treatment (Gr1, p =
0.0042; CD163, p = 0.0007; other markers, p \ 0.0001,
ANOVA).
Fig. 7 Dipyridamole decreases the nuclear expression of phospho-
p65 in vivo. a Representative images of phospho-p65 IHC in sections
of 4T1-Luc primary tumors and MDA-MB-231T lung metastases
from mice treated with intraperitoneally administered PBS-PEG or
dipyridamole (as indicated). b Percentages of phospho-p65 positive
tumor cells nuclei in sections of 4T1-Luc primary tumors from mice
treated with intraperitoneally administered vehicle or dipyridamole
(as indicated). Data are mean ± SEM. p \ 0.0001 (ANOVA).
c Percentages of phospho-p65 positive tumor cells nuclei in sections
of lung metastases from athymic nude mice injected with MDA-MB-
231T cells and treated with vehicle or dipyridamole (intraperitoneal
or oral gavage administration). Data are mean ± SEM. Intraperito-
neal administration p \ 0.0001 (ANOVA)
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Fig. 8 Dipyridamole impairs tumor microenvironment and serum
inflammatory cytokine levels. a Representative images of CD11b,
Gr1, CD163, CD68 and S100A4 IHC in sections of 4T1-Luc primary
tumors from mice treated with intraperitoneally administered PBS-PEG
or dipyridamole (as indicated). b–f Percentage of cells positive to CD11b
b, Gr1 c, CD163 d, CD68 e and S100A4 f in sections of 4T1-Luc primary
tumors as for a. Data are mean ± SEM. b, e, f p \ 0.0001;
c p = 0.0042; d p = 0.0007 (ANOVA). g Absorbances for serum
cytokine levels from 4T1-Luc cell implanted mice treated with PBS-
PEG or dipyridamole (as indicated). Data are mean ± SE. * IL-1b,
p = 0.01; MIP-1a, p = 0.03; SCF, p = 0.03 (Students’ t test)
Clin Exp Metastasis
123
In the tumor microenvironment, we additionally ana-
lyzed the S100A4 protein, a calcium-binding protein of the
S100 protein family, which has an important role in pro-
moting cancer metastasis and invasion [37]. As S100A4 is
a target of the Wnt pathway [38] and an activator of the
NF-kB pathway [39], we investigated S100A4 protein
levels using IHC on sections of the primary tumors from
the breast-cancer xenograft mice that were implanted with
4T1-Luc cells into the mammary fat pad and intraperito-
neally treated with vehicle or 60 mg/kg/day (5 days per
week) dipyridamole. Representative images of this staining
are shown in Fig. 8a. Here, dipyridamole significantly
decreased the percentage of S100A4-positive cells by
18.7 % (Fig. 8f; p \ 0.0001, ANOVA).
In addition, the NF-kB signaling pathway regulates
cytokines production in inflammatory cells [40]. Based on
these data, we further asked whether this intraperitoneal
dipyridamole treatment can influence the serum levels of
the cytokines in this breast-cancer xenograft mouse model.
Here, the 60 mg/kg/day (5 days per week) dipyridamole
treatment of the xenograft mice implanted with 4T1-Luc
cells into the mammary fat pad significantly reduced the
serum levels of IL-1b, MIP-1a and SCF, as compared
to the vehicle treatment (Fig. 8g; p = 0.01, p = 0.03,
p = 0.03, respectively, Students’ t test), with similar trends
seen for other cytokines tested (Fig. 8g; IL-1a, G-CSF,
GM-CSF). Therefore, dipyridamole has in vivo effects on
the NF-kB pathway in both tumor cells and the tumor
microenvironment, which results in negative regulation of
the inflammatory response.
Discussion
In current therapeutic practice, dipyridamole is rarely used
as a single agent. However, an extended-released form of
dipyridamole (Persantin Retard 200 mg) in combination
with aspirin (25 mg) has been designed to take advantage
of the additive antiplatelet effects of both of these agents,
and this combination is used for secondary stroke preven-
tion [19]. Based on the in vitro evidence that dipyridamole
can modulate the cytotoxicity of a variety of antitumor
agents [6–12], phase I and phase II clinical trials of the
combination of dipyridamole and cytotoxic agents were
performed in patients with advanced refractory malignancy
[22–24, 41, 42]. Unfortunately, in these clinical trials, there
were disappointing results in terms of the shrinkage of the
established refractory metastases .
In the present study, we have demonstrated cytostatic
and motility inhibitory effects of single-agent dipyridamole
in vitro, with the concomitant reduction of primary tumor
growth and metastasis formation in vivo. These conflicting
results appear to be attributed to the mode of drug delivery.
Indeed, previous studies showed that, depending upon the
mode of delivery, a broad range of free dipyridamole
concentrations is achieved with the intraperitoneal infusion
more efficient than oral administration or intravenous
infusion [43–45]. This is in keeping with our data, as we
show that administration of dipyridamole by oral gavage is
ineffective in reducing metastasis formation, while intra-
peritoneal delivery of dipyridamole results in significant
reductions in metastasis formation in both of the breast-
cancer xenograft mouse models used here. Based on these
data, it is probable that the limited success of dipyridamole
in the previous clinical trials can be ascribed to its delivery
mode (oral administration or intravenous infusion) [22–24,
41, 42]. Based on our data, we propose that dipyridamole
can be used in the clinic both as a therapeutic agent for the
treatment of triple-negative breast-cancer primary tumors
and as a preventive and therapeutic agent for the treatment
of triple-negative breast-cancer metastasis. Translation of
these data into the clinic awaits further pharmacokinetic
studies.
Another limitation to the clinical application of dipy-
ridamole has been its extensive binding to the serum pro-
tein a1 acid glycoprotein (AGP) [46], an acute-phase
protein that is elevated in the plasma of cancer patients.
The avid binding of dipyridamole to AGP decreases the
free plasma concentrations of dipyridamole to levels that
are insufficient for its therapeutic effects [47]. Recently,
a liposome-based intravenous delivery strategy of dipy-
ridamole in combination with perifosine was used for
inhibition of metastasis in a breast-cancer xenograft model
[25, 26]. This approach thus has the potential to be applied
to clinical trials in humans, to improve the distribution and
delivery of dipyridamole, and to prevent the binding of
dipyridamole to AGP. Additional studies will be required
to address the dipyridamole delivery mode (intraperitoneal
or intravenous delivery by liposomes) and to refine a pro-
posed dose and schedule for dipyridamole treatment that
can be included in a clinical trial.
Several molecular mechanisms might be responsible for
the in vivo therapeutic efficacy of dipyridamole. In Fig. 9,
we summarize the signaling pathways and the biological
processes affected by dipyridamole here investigated at this
time. A few insights on molecular mechanisms by which
dipyridamole inhibits cell proliferation were provided
by Goda and collaborators [15], who described a novel
mechanism of dipyridamole induced G1 arrest in human
osteosarcoma and prostate carcinoma cells [15]. In this
study we further confirm the dipyridamole induces in vitro
G1 cell cycle arrest in breast cancer cells and provide evi-
dence that dipyridamole impairs in vivo the breast cancer
tumor growth in 4T1-Luc breast cancer xenograft models.
In an effort to further unravel the molecular mechanism of
dipyridamole-induced proliferation inhibition we examined
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the signaling pathways perturbation by dipyridamole.
Previous data have established that dipyridamole can
attenuate the NF-kB signaling pathway [32]. In the present
study, we also provide evidence that both in vitro and
in vivo, dipyridamole can attenuate the Wnt signaling
pathway, through reduced b-catenin activation, ERK1/2-
MAPK signaling pathway, through the reduced phosphor-
ylation of ERK1/2, and the NF-kB signaling pathway,
through increased IkBa expression levels, decreased
phosphorylation of p65 and reduced inflammatory cyto-
kines systemic production (including IL-1b, which is
activated by NF-kB with an activation feedback loop). As
all of these signaling pathways promote cell proliferation,
their dipyridamole-induced attenuation might represent a
molecular mechanism by which dipyridamole can reduce
tumor growth.
Literature data provides evidence of ERK1/2-MAPK
signaling in cell migration [48]. Activated ERK regulates
membrane protrusions and focal adhesion turnover via
phosphorylating the myosin light chain kinase (MLCK)
and promotes focal adhesion disassembly via phosphory-
lating and activating calpain protein signal. Moreover the
phosphorylation of FAK and paxillin by ERK may regulate
focal adhesion dynamics, probably by influencing the
paxillin-FAK interaction [48]. Therefore, the ability of
dipyridamole to impair cell motility and metastasis process
might be due to its inhibitory effects on the ERK1/2-
MAPK signaling pathway.
Signaling systems feature extensive crosstalk, and
thereby form a complex network of interactions. Several
previous studies have also shown that Wnt and NF-kB
pathways are linked to each other by a positive-feedback
loop. Kaler et al. described IL-1b as an activator of the Wnt
signaling pathway that acts in a NF-kB-dependent manner
[49]. This suggests that in vivo, the dipyridamole-induced
Wnt pathway attenuation can be further enhanced by
decreased IL-1b expression due to the impairment of the
NF-kB signaling pathway. On the other hand, attenuation
of the Wnt signaling pathway can lead to decreased
expression of S100A4 [38], an important player in tumor
progression and metastasis, and an activator of the NF-kB
signaling pathway [39], thus further attenuating this lat-
ter pathway. A crosstalk with a positive-feedback loop
between the Wnt and ERK pathways has been identified in
tumor cells [50]. The activated ERK induces GSK-3b
inhibition, which stops b-catenin degradation leading to its
accumulation and translocation into the nucleus where b-
catenin forms a complex with TCF. The b-catenin/TCF
complex enhances the expression or activation of the
unknown crosstalk molecules which then activates ERK
via stimulation of Raf-1 and MEK, thus further perpetu-
ating the activation loop [50]. Interestingly, a crosstalk
between ERK-MAPK signaling and NF-kB pathway was
already identified, in which ERK targets IKKa that in turn
phosphorylates IkBa, thus activating NF-kB signaling
pathway [51]. Although the data here presented show that
dipyridamole inhibits Wnt, ERK1/2-MAPK and NF-kB
pathways, at this time it is not possible to determine
whether dipyridamole directly affects at the same time and
all of those pathways. In fact the extensive crosstalk
between these pathways opens the possibility that dipy-
ridamole might target only one or two of these pathways
with consequences on the other(s). The positive-feedback
loop between Wnt and ERK pathways strength this
hypothesis. Moreover, our data show that in vitro dipy-
ridamole treatment for 4 h inhibits Wnt and ERK1/2-
MAPK pathways, but does not impair the NF-kB pathway,
which is then affected only 24 h later during the treatment.
This could lead to the hypothesis that inhibition of NF-kB
is an indirect consequence of the action of dipyridamole on
the previous two affected pathways. Further studies per-
formed with specific inhibitors of these and other pathways
are needed to address this question, thus dissecting further
the mechanism of dipyridamole action.
Another molecular mechanism, by which dipyridamole
might exert its in vivo therapeutic effects is through the
impairment of TAM and MDSC infiltration. Within the
tumor microenvironment, both TAMs and MDSCs have
pro-tumoral functions, which thus promote tumor-cell
survival and proliferation, along with angiogenesis, inces-
sant matrix turnover, dissemination and repression of
adaptive immunity [52, 53]. Therefore, attenuation of the
infiltration of these immune cells might result in reductions
in tumor growth and invasiveness.
Biochemical studies have also identified the transcription
factor NF-kB as a master regulator of cancer-related
Fig. 9 Model of dipyridamole
actions. The model shows the
signaling pathways and the
biological processes affected
by dipyridamole
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inflammation in TAMs and in neoplastic cells. Constitutive
NF-kB activation is indeed often seen in cancer cells, and
this might be promoted by cytokines (e.g., IL-1b and TNFa)
expressed by TAMs or other stromal cells, as well as by
environmental cues (e.g., hypoxia and reactive oxygen
intermediates) or by genetic alterations [54]. NF-kB induces
several cellular modifications associated with tumorigenesis
and with more aggressive phenotypes, which include self-
sufficiency in growth signals, insensitivity to growth inhi-
bition, resistance to apoptotic signals, angiogenesis, and cell
migration and tissue invasion [55]. Therefore, this ability for
dipyridamole to affect the tumor microenvironment might
be due to its inhibitory effects on the NF-kB signaling
pathway. Moreover, given the dipyridamole ability to impair
cell motility, we could not rule out the possibility that the
reduced infiltration of immune cells in the tumor microen-
vironment might be ascribed not only to its inhibitory effects
on the NF-kB signaling pathway but also to its putative
effect on the motility of these cells. Further studies will be
needed to address this question.
In conclusion, the present study provides further insights
into the molecular mechanisms of dipyridamole action,
showing its ability to inhibit triple-negative breast-cancer
primary tumor growth and metastasis formation. Moreover,
our data document the ability of dipyridamole to decrease
the activation of the Wnt, ERK1/2-MAPK and NF-kB
signaling pathways. Finally, we have also described new
biological functions of dipyridamole, showing its attenua-
tion of immune inflammatory cell infiltration, which thus
interferes with metastatic niche formation. We suggest that
with appropriate doses and the correct mode of adminis-
tration, dipyridamole is a promising agent for prevention of
triple-negative primary and metastatic breast cancer, thus
already also implying its potential use in other cancers that
show highly activated Wnt, ERK1/2-MAPK and NF-kB
signaling pathways.
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